carmustine has been researched along with Astrocytoma, Grade IV in 372 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 9.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 9.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "Carmustine wafer implantation during surgical resection followed by the standard chemoradiation protocol for newly diagnosed glioblastoma in adults resulted in a significant progression-free survival benefit." | 9.20 | Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. ( Audureau, E; Barat, JL; Bauchet, L; Caire, F; Corns, R; Desse, N; Devaux, B; Dezamis, E; Duntze, J; Emery, E; Faillot, T; Guyotat, J; Hieu, PD; Langlois, O; Le Reste, PJ; Lechapt-Zalcman, E; Lefranc, M; Litre, CF; Menei, P; Metellus, P; Nader, E; Noel, G; Pallud, J; Parraga, E; Pavlov, V; Peltier, J; Petit, A; Vignes, JR; Voirin, J; Zanello, M, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 9.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 9.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 9.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme." | 9.12 | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. ( Briceño, E; López-González, MA; Sotelo, J, 2006) |
| "In patients with newly diagnosed glioblastoma multiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently with radiation therapy (RT) improves survival compared with BCNU and RT and whether survival using accelerated RT (ART) is equivalent to survival using standard RT (SRT)." | 9.12 | Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group ( Ballman, KV; Buckner, JC; Burton, GV; Cascino, TL; Hawkins, RB; Marks, RS; Michalak, JC; O'Fallon, JR; Sandler, HM; Scheithauer, BW; Schomberg, PJ, 2006) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 9.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 9.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Thirty glioblastoma patients treated at our institute between April 1998 and September 1999 were randomized in a two-arm study to receive carboplatin plus ACNU intraarterial (IA) chemotherapy (arm A) or cisplatin plus BCNU intravenous (IV) treatment (arm B)." | 9.10 | Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. ( Boiardi, A; Eoli, M; Erbetta, A; Fariselli, L; Salmaggi, A; Silvani, A, 2002) |
| "This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme." | 9.10 | Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003) |
| "From May 1990 to November 1994, 70 consecutive patients suffering from glioblastoma multiforme were treated following surgery with conventional radiotherapy and adjuvant IV BCNU administered alone or in combination with tamoxifen." | 9.09 | Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. ( Ameri, A; Broët, P; Cornu, P; Delattre, JY; Keime-Guibert, F; Lafitte, C; Monjour, A; Napolitano, M, 1999) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 9.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 9.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "The aim of this study was to a conduct a systematic review of carmustine wafers (Gliadel wafers) for the treatment of glioblastoma multiforme (GBM) to assess the survival benefit and safety of this therapy." | 8.90 | Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. ( Chen, Z; Dai, RY; He, XZ; Zhang, YD; Zhang, YH; Zhou, J, 2014) |
| "Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect." | 8.12 | Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas. ( Ammar, H; Baroud, M; Benevello, C; Benzakoun, J; Chretien, F; Dezamis, E; Dhermain, F; Moiraghi, A; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Varlet, P; Zah-Bi, G; Zanello, M, 2022) |
| "Patients with a low micro-RNA-181d (miRNA-181d) level in glioblastoma tissue benefit most of carmustine wafer use." | 8.12 | MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use. ( Ketter, R; Oertel, J; Quiring, A; Schulz-Schaeffer, W; Sippl, C; Teping, F; Urbschat, S, 2022) |
| "MiRNA-26a expression turned out to be a promising predictor of therapy response and clinical outcome in glioblastoma patients treated with carmustine wafer implantation." | 7.91 | miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. ( Braun, L; Ketter, R; Kim, YJ; List, M; Nakhoda, A; Oertel, J; Schoeneberger, L; Sippl, C; Teping, F; Urbschat, S; Wemmert, S, 2019) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "For newly diagnosed glioblastomas treated with resection in association with the standard combined chemoradiotherapy, the impact of Carmustine wafer implantation remains debated regarding postoperative infections, quality of life, and feasibility of adjuvant oncological treatments." | 7.85 | Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice. ( Abi Lahoud, G; Bou Nassif, R; Chretien, F; Devaux, B; Dezamis, E; Dhermain, F; Dumont, S; Lechapt-Zalcmann, E; Louvel, G; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Sauvageon, X; Zanello, M, 2017) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 7.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas." | 7.81 | Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas. ( Abi-Lahoud, G; Chrétien, F; Devaux, B; Dezamis, E; Dhermain, F; Domont, J; Louvel, G; Meder, JF; Nataf, F; Page, P; Pallud, J; Parraga, E; Pavlov, V; Robin, A; Souillard-Scemama, R; Turak, B; Varlet, P, 2015) |
| "Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment." | 7.81 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. ( Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM, 2015) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 7.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Innovated catanionic solid lipid nanoparticles (CASLNs) carrying carmustine (BCNU) (BCNU-CASLNs) were grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/BCNU-CASLNs) and applied to inhibiting the propagation of human brain malignant glioblastomas cells." | 7.77 | Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. ( Kuo, YC; Liang, CT, 2011) |
| "Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM)." | 7.75 | Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. ( Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD, 2009) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 7.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Using clonogenic survival assays, we demonstrated that a new platinum-acridine hybrid agent, PT-ACRAMTU, is cytotoxic in SNB19 and U87MG glioblastoma cells at low-micromolar concentrations." | 7.73 | A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. ( Anderson, JG; Bierbach, U; Hess, SM, 2005) |
| "We compared the cytotoxicity of the bioreductive antitumor agents mitomycin C (MMC) and streptonigrin (SN) with or without the DT-diaphorase (DTD) inducer dimethyl fumarate (DMF) in four human glioblastoma cell lines with the conventional chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 7.73 | Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. ( DeAngelis, LM; Gu, B, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 7.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "The human glioblastoma multiforme (GBM) cell line U87 and the rodent C6 glioma were treated with genistein at 4 microM, combined with BCNU (0-50 microM)." | 7.71 | Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. ( Khoshyomn, S; Manske, GC; Nathan, D; Osler, TM; Penar, PL, 2002) |
| "We investigated the potential mechanisms of tamoxifen cytotoxicity in the U-373, U-138, and U-87 human glioblastoma cell lines, namely interference with protein kinase C (PKC) activity, the oestrogen receptor, and/or the production of transforming growth factor beta 1 (TGF-beta 1)." | 7.70 | Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. ( Bernard, EA; da Rocha, AB; Leyva, A; Logullo, AF; Mans, DR; Ruschel, C; Schwartsmann, G; Wetmore, LA, 1999) |
| " The interactions between anticancer drugs such as carmustine (BCNU), vincristine (VCR) and procarbazine (PCB) and calcium channel blockers such as nimodipine and verapamil on cultured cells of glioblastoma from eight patients were therefore tested." | 7.70 | The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. ( Deliorman, S; Durmaz, R; Erol, K; Işiksoy, S; Tel, E; Uyar, R, 1999) |
| "Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose was used to study 10 patients with recurrent glioblastoma before and 24 hours after a first dose of carmustine (120 mg/m2)." | 7.69 | Acute effect of carmustine on glucose metabolism in brain and glioblastoma. ( De Witte, O; Goldman, S; Hildebrand, J; Luxen, A, 1994) |
| "Sequential positron emission tomographic scans with [18F]-2-fluorodeoxyglucose (PET-FDG) were performed on 6 patients with glioblastoma multiforme who were treated with adjuvant BCNU." | 7.68 | Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. ( Cohen, JD; Hanson, JM; Levine, RL; Mehta, MP; Nickles, RJ; Rozental, JM, 1993) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Conventional treatment of glioblastoma multiforme (GBM) cures less than 5% of patients." | 6.71 | Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. ( Brachman, D; Buckner, J; Curran, WJ; Lustig, R; Mehta, MP; Okunieff, P; Podgorsak, EB; Sause, W; Schultz, CJ; Seiferheld, W; Souhami, L; Werner-Wasik, M; Zamorano, L, 2004) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 6.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| "The outcome after treatment for glioblastoma remains poor." | 6.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| " This mathematical model has wide applications about drug release in multiple dosage forms, such as long sustained release microspheres, oral extended release hydrophilic matrix tablets, hydrogel, and sustained release topical rings." | 5.72 | A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma. ( Chen, H; Hu, G; Ouyang, D, 2022) |
| "Carmustine wafers (CW) were approved in Japan for newly diagnosed and recurrent malignant gliomas during 2013." | 5.46 | Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. ( Beppu, T; Kanamori, M; Kawataki, T; Kinouchi, H; Kumabe, T; Matsuda, KI; Nomura, S; Oda, M; Ogasawara, K; Sadahiro, H; Saito, R; Sakurada, K; Sasajima, T; Sato, Y; Shibahara, I; Shimizu, H; Sonoda, Y; Suzuki, M; Tominaga, T, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 5.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome." | 5.38 | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. ( Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K, 2012) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 5.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Carmustine wafer was not an independent predictor (P=." | 5.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 5.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 5.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Retinamide treatment resulted in increased ratios of deamidated verses transamidated levels of Bcl-xL in U87 cells." | 5.33 | Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. ( Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 5.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 5.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 5.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 5.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "Carmustine wafer implantation during surgical resection followed by the standard chemoradiation protocol for newly diagnosed glioblastoma in adults resulted in a significant progression-free survival benefit." | 5.20 | Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. ( Audureau, E; Barat, JL; Bauchet, L; Caire, F; Corns, R; Desse, N; Devaux, B; Dezamis, E; Duntze, J; Emery, E; Faillot, T; Guyotat, J; Hieu, PD; Langlois, O; Le Reste, PJ; Lechapt-Zalcman, E; Lefranc, M; Litre, CF; Menei, P; Metellus, P; Nader, E; Noel, G; Pallud, J; Parraga, E; Pavlov, V; Peltier, J; Petit, A; Vignes, JR; Voirin, J; Zanello, M, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 5.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 5.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 5.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART." | 5.12 | Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. ( Ballman, KV; Buckner, JC; Burton, GV; Cascino, TL; Jaeckle, KA; Marshall, NE; Michalak, JC; Sandler, HM; Schomberg, PJ, 2006) |
| "To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme." | 5.12 | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. ( Briceño, E; López-González, MA; Sotelo, J, 2006) |
| "In patients with newly diagnosed glioblastoma multiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently with radiation therapy (RT) improves survival compared with BCNU and RT and whether survival using accelerated RT (ART) is equivalent to survival using standard RT (SRT)." | 5.12 | Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group ( Ballman, KV; Buckner, JC; Burton, GV; Cascino, TL; Hawkins, RB; Marks, RS; Michalak, JC; O'Fallon, JR; Sandler, HM; Scheithauer, BW; Schomberg, PJ, 2006) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 5.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 5.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Thirty glioblastoma patients treated at our institute between April 1998 and September 1999 were randomized in a two-arm study to receive carboplatin plus ACNU intraarterial (IA) chemotherapy (arm A) or cisplatin plus BCNU intravenous (IV) treatment (arm B)." | 5.10 | Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. ( Boiardi, A; Eoli, M; Erbetta, A; Fariselli, L; Salmaggi, A; Silvani, A, 2002) |
| "This phase III Eastern Cooperative Oncology Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of patients with newly diagnosed glioblastoma multiforme." | 5.10 | Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol ( Gilbert, M; Grossman, SA; Grunnet, M; Hellman, R; Mehta, M; Newton, HB; O'Neill, A; Pearlman, JL; Wagner, H, 2003) |
| "From May 1990 to November 1994, 70 consecutive patients suffering from glioblastoma multiforme were treated following surgery with conventional radiotherapy and adjuvant IV BCNU administered alone or in combination with tamoxifen." | 5.09 | Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study. ( Ameri, A; Broët, P; Cornu, P; Delattre, JY; Keime-Guibert, F; Lafitte, C; Monjour, A; Napolitano, M, 1999) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 5.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks." | 5.07 | Combined intra-arterial chemotherapy and irradiation of malignant gliomas. ( Hager, B; Hirschberg, H; Nome, O; Watne, K, 1991) |
| "Between April 1986 and March 1989, ten patients under 21 years of age with histologically confirmed malignant astrocytoma, received marrow-ablative chemotherapy with either thiotepa and Etoposide (five patients) or thiotepa, Etoposide and BCNU (five patients), followed by bone marrow 'rescue'." | 5.06 | High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. ( August, C; Bayever, E; Finlay, JL; Freid, A; Kamani, N; Kramer, E; Packer, R; Rorke, L; Sutton, L; Zimmerman, R, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 5.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| " Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment)." | 4.93 | Advanced interstitial chemotherapy for treating malignant glioma. ( Kau, YC; Liu, SJ; Tseng, YY, 2016) |
| "Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy." | 4.90 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014) |
| "The aim of this study was to a conduct a systematic review of carmustine wafers (Gliadel wafers) for the treatment of glioblastoma multiforme (GBM) to assess the survival benefit and safety of this therapy." | 4.90 | Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. ( Chen, Z; Dai, RY; He, XZ; Zhang, YD; Zhang, YH; Zhou, J, 2014) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "Loco-regional chemotherapy with carmustine wafers (Gliadel) positioned at surgery and followed by radiotherapy has been shown to prolong survival in first-diagnosis glioblastoma, as well as concomitant radiochemotherapy with temozolomide." | 4.87 | Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. ( Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A, 2011) |
| "Carmustine wafers (Gliadel) and temozolomide (Temodal) were recently approved for initial management of glioblastoma." | 4.84 | [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. ( Ducray, F; Honnorat, J, 2007) |
| "Temozolomide (TMZ) is a new, orally administered, second-generation imidazotetrazine prodrug with essentially 100% oral bioavailability that has demonstrated meaningful efficacy and an acceptable safety profile in the treatment of patients with recurrent glioblastoma multiforme." | 4.80 | Future directions in the treatment of malignant gliomas with temozolomide. ( Prados, MD, 2000) |
| "Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect." | 4.12 | Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas. ( Ammar, H; Baroud, M; Benevello, C; Benzakoun, J; Chretien, F; Dezamis, E; Dhermain, F; Moiraghi, A; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Varlet, P; Zah-Bi, G; Zanello, M, 2022) |
| "Patients with a low micro-RNA-181d (miRNA-181d) level in glioblastoma tissue benefit most of carmustine wafer use." | 4.12 | MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use. ( Ketter, R; Oertel, J; Quiring, A; Schulz-Schaeffer, W; Sippl, C; Teping, F; Urbschat, S, 2022) |
| "The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy." | 4.12 | [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities]. ( Imai, R; Sasaki, H, 2022) |
| "MiRNA-26a expression turned out to be a promising predictor of therapy response and clinical outcome in glioblastoma patients treated with carmustine wafer implantation." | 3.91 | miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. ( Braun, L; Ketter, R; Kim, YJ; List, M; Nakhoda, A; Oertel, J; Schoeneberger, L; Sippl, C; Teping, F; Urbschat, S; Wemmert, S, 2019) |
| "In situ carmustine wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are commonly used for the treatment of recurrent glioblastoma to overcome the brain-blood barrier." | 3.88 | Incomplete copolymer degradation of in situ chemotherapy. ( Apra, C; Boissenot, T; Bourdillon, P; Carpentier, A; Goldwirt, L; Nicolas, J, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts." | 3.88 | Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D, 2018) |
| "For newly diagnosed glioblastomas treated with resection in association with the standard combined chemoradiotherapy, the impact of Carmustine wafer implantation remains debated regarding postoperative infections, quality of life, and feasibility of adjuvant oncological treatments." | 3.85 | Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice. ( Abi Lahoud, G; Bou Nassif, R; Chretien, F; Devaux, B; Dezamis, E; Dhermain, F; Dumont, S; Lechapt-Zalcmann, E; Louvel, G; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Sauvageon, X; Zanello, M, 2017) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 3.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "Solid lipid nanoparticles (SLNs) conjugated with tamoxifen (TX) and lactoferrin (Lf) were applied to carry anticancer carmustine (BCNU) across the blood-brain barrier (BBB) for enhanced antiproliferation against glioblastoma multiforme (GBM)." | 3.83 | Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation. ( Cheng, SJ; Kuo, YC, 2016) |
| "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas." | 3.81 | Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas. ( Abi-Lahoud, G; Chrétien, F; Devaux, B; Dezamis, E; Dhermain, F; Domont, J; Louvel, G; Meder, JF; Nataf, F; Page, P; Pallud, J; Parraga, E; Pavlov, V; Robin, A; Souillard-Scemama, R; Turak, B; Varlet, P, 2015) |
| "Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment." | 3.81 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. ( Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM, 2015) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 3.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity." | 3.78 | Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. ( Dörner, L; Kesari, S; Mehdorn, HM; Nabavi, A; Schultka, S; Spalek, K; Ulmer, S, 2012) |
| "Chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ) is commonly used for the treatment of glioblastoma multiforme (GBM) and other cancers." | 3.78 | In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. ( Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP, 2012) |
| "Innovated catanionic solid lipid nanoparticles (CASLNs) carrying carmustine (BCNU) (BCNU-CASLNs) were grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/BCNU-CASLNs) and applied to inhibiting the propagation of human brain malignant glioblastomas cells." | 3.77 | Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. ( Kuo, YC; Liang, CT, 2011) |
| "Epigenetic silencing of the MGMT gene by promoter methylation is associated with loss of MGMT expression, diminished DNA-repair activity and longer overall survival in patients with glioblastoma who, in addition to radiotherapy, received alkylating chemotherapy with carmustine or temozolomide." | 3.76 | Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. ( Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A, 2010) |
| "Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea." | 3.76 | Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. ( Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH, 2010) |
| " We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy." | 3.76 | First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. ( Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M, 2010) |
| "This study investigated the effect of TNP-470 in combination with carmustine (BCNU) on the growth of subcutaneously implanted human glioblastoma xenografts in nude mice." | 3.76 | Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts. ( Chen, J; Jiang, X; Yao, D; Zhang, F; Zhao, H; Zhu, X, 2010) |
| "Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM)." | 3.75 | Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. ( Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD, 2009) |
| " We report the case of a 57-year-old man who had parietal glioblastoma resection with local carmustine chemotherapy and who presented a clostridial brain abscess three weeks later." | 3.75 | [Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature]. ( Bajolet, O; Duntze, J; Eap, C; Litré, CF; Peruzzi, P; Rousseaux, P; Theret, E, 2009) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 3.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Using clonogenic survival assays, we demonstrated that a new platinum-acridine hybrid agent, PT-ACRAMTU, is cytotoxic in SNB19 and U87MG glioblastoma cells at low-micromolar concentrations." | 3.73 | A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. ( Anderson, JG; Bierbach, U; Hess, SM, 2005) |
| "We compared the cytotoxicity of the bioreductive antitumor agents mitomycin C (MMC) and streptonigrin (SN) with or without the DT-diaphorase (DTD) inducer dimethyl fumarate (DMF) in four human glioblastoma cell lines with the conventional chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.73 | Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. ( DeAngelis, LM; Gu, B, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| " It also showed excellent synergism with N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice." | 3.73 | Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. ( Cho, E; Choi, K; Khosla, C; Omary, B; Piper, JL; Rich, KM; Siegel, M; Strnad, P; Yuan, L, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 3.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| " The typically local recurrence of glioblastoma in about 80% of the cases has prompted intracavitary treatments of which presently only a biodegradable wafer containing carmustine has shown statistically significant benefit regarding survival in three phase III trials." | 3.72 | Intracavitary chemotherapy for glioblastoma: present status and future directions. ( Hilt, D; Lamszus, K; Westphal, M, 2003) |
| "The human glioblastoma multiforme (GBM) cell line U87 and the rodent C6 glioma were treated with genistein at 4 microM, combined with BCNU (0-50 microM)." | 3.71 | Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. ( Khoshyomn, S; Manske, GC; Nathan, D; Osler, TM; Penar, PL, 2002) |
| "Chemosensitivity of previously untreated glioblastomas to mitoxantrone, methotrexate, ACNU and BCNU was tested on cultured tissue." | 3.70 | Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein. ( Damian, MS; Leweke, F; Schachenmayr, W; Schindler, C, 1998) |
| " In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy." | 3.70 | A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998) |
| "We investigated the potential mechanisms of tamoxifen cytotoxicity in the U-373, U-138, and U-87 human glioblastoma cell lines, namely interference with protein kinase C (PKC) activity, the oestrogen receptor, and/or the production of transforming growth factor beta 1 (TGF-beta 1)." | 3.70 | Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. ( Bernard, EA; da Rocha, AB; Leyva, A; Logullo, AF; Mans, DR; Ruschel, C; Schwartsmann, G; Wetmore, LA, 1999) |
| " The interactions between anticancer drugs such as carmustine (BCNU), vincristine (VCR) and procarbazine (PCB) and calcium channel blockers such as nimodipine and verapamil on cultured cells of glioblastoma from eight patients were therefore tested." | 3.70 | The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. ( Deliorman, S; Durmaz, R; Erol, K; Işiksoy, S; Tel, E; Uyar, R, 1999) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose was used to study 10 patients with recurrent glioblastoma before and 24 hours after a first dose of carmustine (120 mg/m2)." | 3.69 | Acute effect of carmustine on glucose metabolism in brain and glioblastoma. ( De Witte, O; Goldman, S; Hildebrand, J; Luxen, A, 1994) |
| "Sequential positron emission tomographic scans with [18F]-2-fluorodeoxyglucose (PET-FDG) were performed on 6 patients with glioblastoma multiforme who were treated with adjuvant BCNU." | 3.68 | Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. ( Cohen, JD; Hanson, JM; Levine, RL; Mehta, MP; Nickles, RJ; Rozental, JM, 1993) |
| "This study was designed to determine whether resistance to the activity of nitrosourea (the drug BCNU) in BCNU-resistant human medulloblastoma (D341 Med) and human glioblastoma multiforme (D-456 MG) can be reversed by the methylating agent streptozocin and the O6-substituted guanines O6-methylguanine and O6-benzylguanine." | 3.68 | Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. ( Bigner, DD; Dolan, ME; Felker, GM; Friedman, HS; Moschel, RC; Pegg, AE; Rich, J; Schold, SC, 1992) |
| "Intensive monochemotherapy with carmustine (BCNU) (either 1,050, 1,200, or 1,350 mg/m2) and cryopreserved autologous marrow transplantation was administered to 36 patients with malignant glioma: 27 with progressive disease and nine without progression (adjuvant therapy group)." | 3.67 | Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. ( Fay, JW; Herzig, GP; Herzig, RH; Lazarus, HM; Phillips, GL; Schold, C; Wolff, SN, 1986) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Glioblastoma is the commonest primary brain cancer in adults whose outcomes are amongst the worst of any cancer." | 2.82 | Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature. ( Akkari, L; Borst, GR; Coope, DJ; McBain, C; O'Connor, J; Quinones-Hinojosa, A; Trifiletti, DM; Waqar, M, 2022) |
| "Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas." | 2.75 | Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. ( Ames, MM; Arusell, R; Ballman, KV; Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Hammack, JE; Jaeckle, KA; McGovern, RM; Morton, RF; Nikcevich, DA; Reid, JM; Safgren, SL; Schomberg, PJ; Uhm, JH; Wender, DB, 2010) |
| "Carmustine 80 mg/m(2) was given during RT, then every 8 weeks for 6 cycles." | 2.74 | Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. ( Curran, WJ; Diaz, A; Gilbert, MR; Kresel, JJ; Mehta, MP; Michalski, JM; Moughan, J; Purdy, J; Simpson, J; Tsien, C, 2009) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Conventional treatment of glioblastoma multiforme (GBM) cures less than 5% of patients." | 2.71 | Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. ( Brachman, D; Buckner, J; Curran, WJ; Lustig, R; Mehta, MP; Okunieff, P; Podgorsak, EB; Sause, W; Schultz, CJ; Seiferheld, W; Souhami, L; Werner-Wasik, M; Zamorano, L, 2004) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 2.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "The outcome after treatment for glioblastoma remains poor." | 2.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | 2.69 | Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| "Histology included anaplastic astrocytoma (AA) in 15 patients and glioblastoma multiforme (GBM) in 49 patients." | 2.68 | Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. ( Antunovic, V; Djuric, L; Grujicic, D; Jeremic, B; Shibamoto, Y, 1995) |
| "Patients with anaplastic astrocytoma, or glioblastoma multiforme, age 18-70 years with a Karnofsky performance status of 40-100 were stratified according to age, Karnofsky performance status, and histology, and were randomized." | 2.67 | Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. ( Ahmad, K; Constine, LS; Curran, WJ; Mohiuddin, M; Murray, K; Nelson, DF; Nelson, JS; Powlis, WD; Scott, C; Weinstein, AS, 1993) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Temozolomide (TMZ) is a DNA-methylating agent." | 2.53 | Current and Future Drug Treatments for Glioblastomas. ( Hirose, Y; Ohba, S, 2016) |
| "Glioblastoma is the most common adult malignant primary brain tumor." | 2.52 | Current medical treatment of glioblastoma. ( Ahluwalia, MS; Peereboom, DM; Venur, VA, 2015) |
| "Temozolomide has demonstrated a 2." | 2.50 | A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. ( Hay, JW; Messali, A; Villacorta, R, 2014) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Temozolomide (TMZ) has emerged as an active agent against malignant gliomas." | 2.44 | Management of glioblastoma. ( Aoki, T; Hashimoto, N; Matsutani, M, 2007) |
| "Use of interstitial BCNU wafers in the treatment of malignant glioma is currently a controversial topic among neurosurgeons." | 2.41 | The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. ( Engelhard, HH, 2000) |
| "Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed." | 2.41 | Drug delivery to tumors of the central nervous system. ( Brem, H; Langer, R; Lesniak, MS, 2001) |
| "Human malignant gliomas are karyotypically heterogeneous, composed of many cellular populations and isolated cell types identifiable by cytogenetic techniques." | 2.37 | The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro. ( Shapiro, JR; Shapiro, WR, 1985) |
| " This mathematical model has wide applications about drug release in multiple dosage forms, such as long sustained release microspheres, oral extended release hydrophilic matrix tablets, hydrogel, and sustained release topical rings." | 1.72 | A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma. ( Chen, H; Hu, G; Ouyang, D, 2022) |
| " In a drug screening assay, diffusion of temozolomide and carmustine to hydrogel-encapsulated U87 cells from the perfusion solution is measured, and dose-response curves are generated, demonstrating utility as an in vitro mimic of the glioblastoma microenvironment." | 1.72 | Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture. ( Bruns, J; Chen, D; Clancy, A; Nadella, J; Stealey, S; Timperman, A; Zhang, Y; Zustiak, SP, 2022) |
| "BCNU wafer implantation after resection of recurrent GBM is a reasonably safe treatment in patients aged >65 years." | 1.46 | Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma. ( Daubner, D; Juratli, TA; Klein, J; Krex, D; Radev, Y; Schackert, G; Soucek, S, 2017) |
| "Carmustine wafers (CW) were approved in Japan for newly diagnosed and recurrent malignant gliomas during 2013." | 1.46 | Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. ( Beppu, T; Kanamori, M; Kawataki, T; Kinouchi, H; Kumabe, T; Matsuda, KI; Nomura, S; Oda, M; Ogasawara, K; Sadahiro, H; Saito, R; Sakurada, K; Sasajima, T; Sato, Y; Shibahara, I; Shimizu, H; Sonoda, Y; Suzuki, M; Tominaga, T, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 1.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Glioblastoma multiforme is the most common malignant central nervous system tumor, and also among the most difficult to treat due to a lack of response to chemotherapeutics." | 1.39 | Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. ( Payne, CA; Safdar, S; Taite, LJ; Tu, NH, 2013) |
| " This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs." | 1.39 | Effective elimination of cancer stem cells by a novel drug combination strategy. ( Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| "Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome." | 1.38 | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. ( Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K, 2012) |
| " The rate of adverse events, especially hematological toxicity, is relatively high, and in 3 patients treatment had to be terminated due to adverse events (one pulmonary embolism, one pulmonary fibrosis, and one severe bone marrow suppression)." | 1.36 | BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. ( Graf, E; Nikkhah, G; Pinsker, MO; Piroth, T; Reithmeier, T; Trippel, M, 2010) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 1.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Carmustine wafer was not an independent predictor (P=." | 1.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 1.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 1.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Glioblastoma is the most common primary brain tumour with poor overall survival." | 1.34 | Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence. ( Ng, WH; Too, HP; Wan, GQ, 2007) |
| "Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM)." | 1.34 | Imaging response in malignant glioma, RTOG 90-06. ( Berkey, B; Curran, WJ; Fishbach, J; Jones, CU; Lustig, RA; Movsas, B; Scarantino, C; Seiferheld, W; Simpson, JR; Yung, AW, 2007) |
| "Valproic acid (VPA) has been recently investigated for its anticancer properties in different tumors, including malignant gliomas." | 1.34 | Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A, 2007) |
| "Retinamide treatment resulted in increased ratios of deamidated verses transamidated levels of Bcl-xL in U87 cells." | 1.33 | Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. ( Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) |
| "We identified a transcriptomic signature that predicts a common in vitro and in vivo resistance phenotype to these agents, a proportion of which is imprinted recurrently by gene dosage changes in the resistant glioblastoma genome." | 1.33 | Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. ( Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX, 2006) |
| "In all cell lines tested, treatment of glioblastoma multiforme cells with BCNU followed by AMD3100 results in synergistic antitumor efficacy in vitro." | 1.33 | CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. ( Chan, JA; Kung, AL; Redjal, N; Segal, RA, 2006) |
| "Out of 26 patients with anaplastic astrocytomas 11 were originally low-grade where no postoperative radiotherapy was applied." | 1.31 | BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "The hypodense, roughly spherical cysts clearly demonstrated clinically significant mass effect, and required reoperation despite treatment with high-dose corticosteroids." | 1.31 | Tumor bed cyst formation after BCNU wafer implantation: report of two cases. ( Engelhard, HH, 2000) |
| " Currently, SU101 in combination with cytotoxic agents is in late-stage clinical development for the treatment of cancers." | 1.31 | Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. ( Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM, 2000) |
| " Additionally, we investigated a potential enhancement of the antitumoral action of thalidomide when combined with a low dose of the antineoplastic carmustine." | 1.31 | Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. ( Arrieta, O; Guevara, P; Rembao, D; Rivera, E; Sotelo, J; Tamariz, J, 2002) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 1.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "A 35-year-old man presented with partial seizures 10 years after resection of a left-sided glioblastoma multiforme." | 1.30 | Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. ( Cecil, KM; Hackney, DB; Lenkinski, RE; Pruitt, AA; Quan, D, 1999) |
| " The solubility, metabolism, bioavailability and effectiveness of O6-benzylguanine as an adjuvant therapy with BCNU were compared using two vehicles, cremophor-EL and PEG 400." | 1.29 | Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. ( Dolan, ME; Flora, KP; Friedman, HS; Grever, MR; Moschel, RC; Pegg, AE; Vishnuvajjala, BR, 1994) |
| "The SF-767 brain tumors were extremely responsive to BE-4-4-4-4 alone (3 of 8 complete regressions after 2 cycles); however, the growth of the U-87 MG brain tumor was only slightly inhibited by BE-4-4-4-4 treatment." | 1.29 | Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. ( Basu, HS; Casero, RA; Dolan, ME; Feuerstein, BG; Fleig, MJ; Luk, GD; Marton, LJ, 1994) |
| "Seven of ten anaplastic astrocytomas were composed primarily of 2n+/- cells and were BCNU resistant." | 1.29 | Chromosome number and carmustine sensitivity in human gliomas. ( Ebrahim, SA; Galicich, JH; Mohamed, AN; Pu, PY; Shapiro, JR; Shapiro, WR, 1993) |
| "Recurrent gliomas are most often treated by chemotherapy." | 1.29 | Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. ( Liang, BC, 1996) |
| " Occurrence of such leukoencephalopathy is not always predictable based on BCNU dosage and cannot always be reliably distinguished from tumor regrowth or tumor necrosis by radiological and clinical evaluation." | 1.28 | Pathology of high-dose intraarterial BCNU. ( Geier, JM; Kleinschmidt-DeMasters, BK, 1989) |
| " The kinetics and dose-response relationship of this interaction were determined by measuring residual GSH and residual BCNU-cytotoxicity in aGSH/BCNU mixture over a 45-min period and at varying BCNU concentrations." | 1.28 | Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. ( Ali-Osman, F; Caughlan, J; Gray, GS, 1989) |
| " Sorted populations of cells from 5 tumors had dose-response curves that were similar, although differences in cell kill of up to a half-log were commonly found between cells from different DNA peaks treated with the same BCNU dose." | 1.27 | Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content. ( Dougherty, DV; Hoshino, T; Kobayashi, S; Rosenblum, ML, 1984) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "Fatal leukoencephalopathy occurred in two patients." | 1.27 | Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. ( Bashir, R; Hochberg, FH; Hottleman, K; Linggood, RM, 1988) |
| " The shapes of the dose-response curves indicated complete cross-resistance between BCNU and CCNU, i." | 1.27 | In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. ( Bricolo, A; Della Corte, V; Gerosa, MA; Licata, C; Marcon, C; Rosenblum, ML; Stevanoni, G; Tridente, G, 1986) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 1.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| "Glioblastoma multiforme is composed of multiple cellular compartments with different morphologic, kinetic, metabolic, vascular, and genetic properties." | 1.26 | Aggressive multimodality therapy based on a multicompartmental model of glioblastoma. ( Broadwell, RD; Ducker, TB; Kaplan, RS; Salcman, M; Samaras, GM, 1982) |
| "Seven human brain tumors were transplanted into the brains (6/7 takes) and subcutaneous tissues (7/7 takes) of athymic nude mice." | 1.26 | Human brain tumor transplantation into nude mice. ( Basler, GA; Chernik, NL; Posner, JB; Shapiro, WR, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 74 (19.89) | 18.7374 |
| 1990's | 70 (18.82) | 18.2507 |
| 2000's | 102 (27.42) | 29.6817 |
| 2010's | 109 (29.30) | 24.3611 |
| 2020's | 17 (4.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hess, SM | 1 |
| Anderson, JG | 1 |
| Bierbach, U | 1 |
| Clarion, L | 1 |
| Jacquard, C | 1 |
| Sainte-Catherine, O | 1 |
| Loiseau, S | 1 |
| Filippini, D | 1 |
| Hirlemann, MH | 1 |
| Volle, JN | 1 |
| Virieux, D | 1 |
| Lecouvey, M | 1 |
| Pirat, JL | 1 |
| Bakalara, N | 1 |
| Roux, A | 4 |
| Ammar, H | 1 |
| Moiraghi, A | 2 |
| Peeters, S | 2 |
| Baroud, M | 1 |
| Zah-Bi, G | 2 |
| Benzakoun, J | 1 |
| Parraga, E | 5 |
| Oppenheim, C | 3 |
| Benevello, C | 2 |
| Chretien, F | 4 |
| Varlet, P | 2 |
| Dhermain, F | 3 |
| Dezamis, E | 5 |
| Zanello, M | 5 |
| Pallud, J | 6 |
| Chen, H | 1 |
| Hu, G | 1 |
| Ouyang, D | 1 |
| Sippl, C | 3 |
| Quiring, A | 1 |
| Teping, F | 2 |
| Schulz-Schaeffer, W | 1 |
| Urbschat, S | 3 |
| Ketter, R | 4 |
| Oertel, J | 3 |
| Waqar, M | 1 |
| Trifiletti, DM | 1 |
| McBain, C | 1 |
| O'Connor, J | 1 |
| Coope, DJ | 1 |
| Akkari, L | 1 |
| Quinones-Hinojosa, A | 7 |
| Borst, GR | 1 |
| Sun, X | 1 |
| Fan, T | 1 |
| Sun, G | 1 |
| Zhou, Y | 1 |
| Huang, Y | 1 |
| Zhang, N | 1 |
| Zhao, L | 1 |
| Zhong, R | 1 |
| Peng, Y | 1 |
| Imai, R | 1 |
| Sasaki, H | 1 |
| Shibahara, I | 5 |
| Shibahara, Y | 1 |
| Hagiwara, H | 1 |
| Watanabe, T | 3 |
| Orihashi, Y | 1 |
| Handa, H | 1 |
| Inukai, M | 3 |
| Hide, T | 2 |
| Yasui, Y | 3 |
| Kumabe, T | 6 |
| Ahmad, S | 1 |
| Khan, I | 1 |
| Pandit, J | 1 |
| Emad, NA | 1 |
| Bano, S | 1 |
| Dar, KI | 1 |
| Rizvi, MMA | 1 |
| Ansari, MD | 1 |
| Aqil, M | 1 |
| Sultana, Y | 1 |
| Radtke, L | 1 |
| Majchrzak-Celińska, A | 1 |
| Awortwe, C | 1 |
| Vater, I | 1 |
| Nagel, I | 1 |
| Sebens, S | 1 |
| Cascorbi, I | 1 |
| Kaehler, M | 1 |
| Clancy, A | 1 |
| Chen, D | 1 |
| Bruns, J | 1 |
| Nadella, J | 1 |
| Stealey, S | 1 |
| Zhang, Y | 1 |
| Timperman, A | 1 |
| Zustiak, SP | 1 |
| Das, D | 1 |
| Narayanan, D | 1 |
| Ramachandran, R | 1 |
| Gowd, GS | 1 |
| Manohar, M | 1 |
| Arumugam, T | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Aboubakr, O | 1 |
| Elia, A | 1 |
| Fathallah, H | 1 |
| Böhlen, TT | 1 |
| Germond, JF | 1 |
| Traneus, E | 1 |
| Vallet, V | 1 |
| Desorgher, L | 1 |
| Ozsahin, EM | 1 |
| Bochud, F | 1 |
| Bourhis, J | 1 |
| Moeckli, R | 1 |
| Braun, L | 1 |
| Schoeneberger, L | 1 |
| Kim, YJ | 2 |
| List, M | 2 |
| Nakhoda, A | 1 |
| Wemmert, S | 1 |
| Kadota, T | 1 |
| Saito, R | 3 |
| Mizusawa, J | 1 |
| Katayama, H | 1 |
| Sumi, M | 1 |
| Igaki, H | 1 |
| Kinoshita, M | 1 |
| Komori, T | 1 |
| Ichimura, K | 1 |
| Narita, Y | 1 |
| Nishikawa, R | 2 |
| Rezaei, T | 1 |
| Hejazi, M | 1 |
| Mansoori, B | 1 |
| Mohammadi, A | 1 |
| Amini, M | 1 |
| Mosafer, J | 1 |
| Rezaei, S | 1 |
| Mokhtarzadeh, A | 1 |
| Baradaran, B | 1 |
| Erthal, LCS | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Mathen, P | 1 |
| Smart, DK | 1 |
| Miyasaka, K | 1 |
| Sekiguchi, A | 1 |
| Ishiyama, H | 1 |
| Sato, S | 2 |
| Klein, J | 1 |
| Juratli, TA | 1 |
| Radev, Y | 1 |
| Daubner, D | 1 |
| Soucek, S | 1 |
| Schackert, G | 1 |
| Krex, D | 1 |
| Beez, T | 1 |
| Burgula, S | 1 |
| Kamp, M | 1 |
| Rapp, M | 1 |
| Steiger, HJ | 2 |
| Sabel, M | 2 |
| Illic, R | 1 |
| Somma, T | 1 |
| Savic, D | 1 |
| Frio, F | 1 |
| Milicevic, M | 1 |
| Solari, D | 1 |
| Nikitovic, M | 1 |
| Lavrnic, S | 1 |
| Raicevic, S | 1 |
| Milosevic, S | 1 |
| Cavallo, LM | 1 |
| Cappabianca, P | 1 |
| Grujicic, D | 4 |
| Sonoda, Y | 1 |
| Matsuda, KI | 1 |
| Kawataki, T | 1 |
| Oda, M | 1 |
| Sato, Y | 1 |
| Sadahiro, H | 1 |
| Nomura, S | 1 |
| Sasajima, T | 1 |
| Beppu, T | 1 |
| Kanamori, M | 1 |
| Sakurada, K | 1 |
| Tominaga, T | 1 |
| Kinouchi, H | 1 |
| Shimizu, H | 1 |
| Ogasawara, K | 1 |
| Suzuki, M | 1 |
| Bou Nassif, R | 1 |
| Abi Lahoud, G | 1 |
| Lechapt-Zalcmann, E | 1 |
| Dumont, S | 1 |
| Louvel, G | 3 |
| Sauvageon, X | 1 |
| Devaux, B | 3 |
| Doishita, S | 1 |
| Shimono, T | 1 |
| Yoneda, T | 1 |
| Yamada, E | 1 |
| Tsukamoto, T | 1 |
| Takemori, D | 1 |
| Kimura, D | 1 |
| Tatekawa, H | 1 |
| Sakamoto, S | 1 |
| Miki, Y | 1 |
| Sage, W | 1 |
| Guilfoyle, M | 1 |
| Luney, C | 1 |
| Young, A | 1 |
| Sinha, R | 1 |
| Sgubin, D | 1 |
| McAbee, JH | 1 |
| Ma, R | 1 |
| Jefferies, S | 1 |
| Jena, R | 1 |
| Harris, F | 1 |
| Allinson, K | 1 |
| Matys, T | 1 |
| Qian, W | 1 |
| Santarius, T | 1 |
| Price, S | 1 |
| Watts, C | 3 |
| Bourdillon, P | 1 |
| Boissenot, T | 1 |
| Goldwirt, L | 1 |
| Nicolas, J | 1 |
| Apra, C | 1 |
| Carpentier, A | 1 |
| Hanihara, M | 1 |
| Dan, M | 1 |
| Kuroda, H | 1 |
| Inamura, A | 1 |
| Hara, A | 1 |
| Akiyama, Y | 1 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Rudra, S | 1 |
| Hui, C | 1 |
| Rao, YJ | 1 |
| Samson, P | 1 |
| Lin, AJ | 1 |
| Chang, X | 1 |
| Tsien, C | 2 |
| Fergus, S | 1 |
| Mullen, D | 1 |
| Yang, D | 1 |
| Thotala, D | 1 |
| Hallahan, D | 1 |
| Campian, JL | 1 |
| Huang, J | 1 |
| Grangeon, L | 1 |
| Ferracci, FX | 1 |
| Fetter, D | 1 |
| Maltete, D | 1 |
| Langlois, O | 2 |
| Gilard, V | 1 |
| Tiek, DM | 1 |
| Rone, JD | 1 |
| Graham, GT | 1 |
| Pannkuk, EL | 1 |
| Haddad, BR | 1 |
| Riggins, RB | 1 |
| Bohr, L | 1 |
| Dos Santos, CJ | 1 |
| Ferreira Castro, FL | 1 |
| de Aguiar, RB | 1 |
| Menezes, IG | 1 |
| Santos, AC | 1 |
| Paulus, C | 1 |
| Nevels, M | 1 |
| Carlan da Silva, MC | 1 |
| Chen, C | 2 |
| Han, G | 1 |
| Li, Y | 1 |
| Yue, Z | 1 |
| Wang, L | 2 |
| Liu, J | 1 |
| Shapira-Furman, T | 1 |
| Serra, R | 1 |
| Gorelick, N | 1 |
| Doglioli, M | 1 |
| Tagliaferri, V | 1 |
| Cecia, A | 1 |
| Peters, M | 1 |
| Kumar, A | 1 |
| Rottenberg, Y | 1 |
| Langer, R | 3 |
| Brem, H | 10 |
| Tyler, B | 3 |
| Domb, AJ | 1 |
| Tabet, A | 1 |
| Jensen, MP | 1 |
| Parkins, CC | 1 |
| Patil, PG | 1 |
| Scherman, OA | 1 |
| Cardona, AF | 1 |
| Rojas, L | 1 |
| Wills, B | 1 |
| Ruiz-Patiño, A | 1 |
| Abril, L | 1 |
| Hakim, F | 1 |
| Jiménez, E | 1 |
| Useche, N | 1 |
| Bermúdez, S | 1 |
| Mejía, JA | 1 |
| Ramón, JF | 1 |
| Carranza, H | 1 |
| Vargas, C | 2 |
| Otero, J | 1 |
| Archila, P | 1 |
| Rodríguez, J | 2 |
| Behaine, J | 1 |
| González, D | 1 |
| Jacobo, J | 1 |
| Cifuentes, H | 1 |
| Feo, O | 1 |
| Penagos, P | 1 |
| Pineda, D | 1 |
| Ricaurte, L | 1 |
| Pino, LE | 1 |
| Marquez, JC | 1 |
| Mantilla, MI | 1 |
| Ortiz, LD | 1 |
| Balaña, C | 2 |
| Rosell, R | 2 |
| Zatarain-Barrón, ZL | 1 |
| Arrieta, O | 3 |
| Gutenberg, A | 1 |
| Bock, HC | 4 |
| Brück, W | 1 |
| Doerner, L | 1 |
| Mehdorn, HM | 3 |
| Roggendorf, W | 1 |
| Westphal, M | 6 |
| Felsberg, J | 1 |
| Reifenberger, G | 1 |
| Giese, A | 4 |
| Mullins, CS | 1 |
| Schneider, B | 1 |
| Stockhammer, F | 1 |
| Krohn, M | 1 |
| Classen, CF | 1 |
| Linnebacher, M | 1 |
| Qian, L | 1 |
| Zheng, J | 1 |
| Wang, K | 1 |
| Tang, Y | 1 |
| Zhang, X | 1 |
| Zhang, H | 2 |
| Huang, F | 1 |
| Pei, Y | 1 |
| Jiang, Y | 1 |
| Yi, N | 1 |
| Oh, B | 1 |
| Kim, HA | 1 |
| Lee, M | 1 |
| Bregy, A | 1 |
| Shah, AH | 1 |
| Diaz, MV | 1 |
| Pierce, HE | 1 |
| Ames, PL | 1 |
| Diaz, D | 1 |
| Komotar, RJ | 1 |
| Chamberlain, MC | 2 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 1 |
| Isik, G | 1 |
| Hänggi, D | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 1 |
| Shah, RS | 1 |
| Homapour, B | 1 |
| Casselden, E | 1 |
| Barr, JG | 2 |
| Grundy, PL | 2 |
| Brydon, HL | 1 |
| Stevens, BM | 1 |
| Folts, CJ | 1 |
| Cui, W | 1 |
| Bardin, AL | 1 |
| Walter, K | 1 |
| Carson-Walter, E | 1 |
| Vescovi, A | 1 |
| Noble, M | 1 |
| Olson, JJ | 2 |
| Nayak, L | 2 |
| Ormond, DR | 1 |
| Wen, PY | 2 |
| Kalkanis, SN | 1 |
| Xie, Q | 1 |
| Yan, Y | 1 |
| Huang, Z | 1 |
| Zhong, X | 1 |
| Huang, L | 1 |
| Cecchin, D | 2 |
| Schiorlin, I | 1 |
| Della Puppa, A | 3 |
| Lombardi, G | 3 |
| Zucchetta, P | 1 |
| Bodanza, V | 1 |
| Gardiman, MP | 2 |
| Rolma, G | 2 |
| Frigo, AC | 1 |
| Bui, F | 1 |
| Zustovich, F | 1 |
| Pambuku, A | 1 |
| Farina, P | 1 |
| Fiduccia, P | 1 |
| Roma, A | 1 |
| Zagonel, V | 2 |
| Rahman, R | 1 |
| Hempfling, K | 1 |
| Norden, AD | 1 |
| Reardon, DA | 6 |
| Rinne, ML | 1 |
| Beroukhim, R | 1 |
| Doherty, L | 1 |
| Ruland, S | 1 |
| Rai, A | 1 |
| Rifenburg, J | 1 |
| LaFrankie, D | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Lee, EQ | 1 |
| Messali, A | 1 |
| Villacorta, R | 1 |
| Hay, JW | 1 |
| Adair, JE | 1 |
| Johnston, SK | 1 |
| Mrugala, MM | 1 |
| Beard, BC | 2 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Hawkins-Daarud, A | 1 |
| Gori, JL | 2 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Rockne, RC | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 1 |
| Swanson, KR | 1 |
| Kiem, HP | 2 |
| Zhang, YD | 1 |
| Dai, RY | 1 |
| Chen, Z | 1 |
| Zhang, YH | 1 |
| He, XZ | 1 |
| Zhou, J | 1 |
| Blumenthal, DT | 1 |
| Rankin, C | 1 |
| Stelzer, KJ | 1 |
| Spence, AM | 1 |
| Sloan, AE | 1 |
| Moore, DF | 1 |
| Padula, GD | 1 |
| Schulman, SB | 1 |
| Wade, ML | 1 |
| Rushing, EJ | 1 |
| Venur, VA | 1 |
| Peereboom, DM | 1 |
| Ahluwalia, MS | 1 |
| Pavlov, V | 2 |
| Page, P | 1 |
| Abi-Lahoud, G | 1 |
| Nataf, F | 1 |
| Robin, A | 1 |
| Turak, B | 1 |
| Domont, J | 1 |
| Souillard-Scemama, R | 1 |
| Meder, JF | 1 |
| Wait, SD | 1 |
| Prabhu, RS | 1 |
| Burri, SH | 1 |
| Atkins, TG | 1 |
| Asher, AL | 1 |
| Chaichana, KL | 5 |
| Kone, L | 1 |
| Bettegowda, C | 2 |
| Weingart, JD | 5 |
| Olivi, A | 7 |
| Lim, M | 2 |
| Gallia, GL | 2 |
| McFaline-Figueroa, JL | 1 |
| Braun, CJ | 1 |
| Stanciu, M | 1 |
| Nagel, ZD | 1 |
| Mazzucato, P | 1 |
| Sangaraju, D | 1 |
| Cerniauskas, E | 1 |
| Barford, K | 1 |
| Vargas, A | 1 |
| Chen, Y | 1 |
| Tretyakova, N | 1 |
| Lees, JA | 1 |
| Hemann, MT | 1 |
| White, FM | 1 |
| Samson, LD | 1 |
| Xing, WK | 1 |
| Shao, C | 1 |
| Qi, ZY | 1 |
| Yang, C | 1 |
| Wang, Z | 2 |
| Audureau, E | 1 |
| Noel, G | 3 |
| Corns, R | 1 |
| Lechapt-Zalcman, E | 2 |
| Duntze, J | 2 |
| Guyotat, J | 1 |
| Hieu, PD | 2 |
| Le Reste, PJ | 1 |
| Faillot, T | 1 |
| Litre, CF | 2 |
| Desse, N | 1 |
| Petit, A | 1 |
| Emery, E | 2 |
| Voirin, J | 1 |
| Peltier, J | 1 |
| Caire, F | 1 |
| Vignes, JR | 1 |
| Barat, JL | 1 |
| Nader, E | 1 |
| Lefranc, M | 1 |
| Bauchet, L | 1 |
| Menei, P | 3 |
| Metellus, P | 3 |
| Tseng, YY | 2 |
| Wang, YC | 1 |
| Su, CH | 1 |
| Yang, TC | 1 |
| Chang, TM | 1 |
| Kau, YC | 2 |
| Liu, SJ | 2 |
| Nakase, K | 1 |
| Matsuda, R | 1 |
| Nishimura, F | 1 |
| Nakamura, M | 1 |
| Motoyama, Y | 1 |
| Park, YS | 1 |
| Nakase, H | 1 |
| Grossman, R | 2 |
| Burger, P | 2 |
| Soudry, E | 1 |
| Weingart, J | 1 |
| Sidransky, D | 1 |
| Ye, X | 2 |
| Chakrabarti, M | 1 |
| Ray, SK | 1 |
| Stupp, R | 1 |
| Taillibert, S | 1 |
| Kanner, AA | 1 |
| Kesari, S | 2 |
| Steinberg, DM | 1 |
| Toms, SA | 1 |
| Taylor, LP | 1 |
| Lieberman, F | 1 |
| Silvani, A | 8 |
| Fink, KL | 2 |
| Barnett, GH | 1 |
| Zhu, JJ | 1 |
| Henson, JW | 1 |
| Engelhard, HH | 3 |
| Chen, TC | 1 |
| Tran, DD | 1 |
| Sroubek, J | 1 |
| Tran, ND | 1 |
| Hottinger, AF | 1 |
| Landolfi, J | 1 |
| Desai, R | 1 |
| Caroli, M | 1 |
| Kew, Y | 1 |
| Honnorat, J | 3 |
| Idbaih, A | 1 |
| Kirson, ED | 1 |
| Weinberg, U | 1 |
| Palti, Y | 1 |
| Hegi, ME | 1 |
| Ram, Z | 3 |
| Kuo, YC | 2 |
| Cheng, SJ | 1 |
| Paul-Samojedny, M | 1 |
| Pudełko, A | 1 |
| Kowalczyk, M | 1 |
| Fila-Daniłow, A | 1 |
| Suchanek-Raif, R | 1 |
| Borkowska, P | 1 |
| Kowalski, J | 1 |
| Ashby, LS | 2 |
| Smith, KA | 2 |
| Stea, B | 1 |
| Rossetto, M | 1 |
| Rustemi, O | 1 |
| Berti, F | 4 |
| Persano, L | 1 |
| Scienza, R | 2 |
| Ohba, S | 1 |
| Hirose, Y | 1 |
| Mathios, D | 1 |
| Kim, JE | 1 |
| Mangraviti, A | 1 |
| Phallen, J | 1 |
| Park, CK | 1 |
| Jackson, CM | 1 |
| Garzon-Muvdi, T | 1 |
| Kim, E | 1 |
| Theodros, D | 1 |
| Polanczyk, M | 1 |
| Martin, AM | 1 |
| Suk, I | 1 |
| Pardoll, DM | 1 |
| Juillerat-Jeanneret, L | 1 |
| Bernasconi, CC | 1 |
| Bricod, C | 1 |
| Gros, S | 1 |
| Trepey, S | 1 |
| Benhattar, J | 1 |
| Janzer, RC | 1 |
| Kang, MK | 1 |
| Kang, SK | 1 |
| Esther Gil-Alegre, M | 1 |
| González-Alvarez, I | 1 |
| Gutiérrez-Paúls, L | 1 |
| Torres-Suárez, AI | 1 |
| Attenello, FJ | 2 |
| Mukherjee, D | 1 |
| Datoo, G | 1 |
| McGirt, MJ | 3 |
| Bohan, E | 1 |
| McKenzie, E | 1 |
| Skurski-Martin, M | 1 |
| Zhang, Z | 1 |
| Brat, D | 1 |
| Phuphanich, S | 2 |
| Moughan, J | 1 |
| Michalski, JM | 1 |
| Gilbert, MR | 1 |
| Purdy, J | 2 |
| Simpson, J | 2 |
| Kresel, JJ | 1 |
| Curran, WJ | 8 |
| Diaz, A | 2 |
| Mehta, MP | 5 |
| Pédeboscq, S | 1 |
| L'Azou, B | 1 |
| Passagne, I | 1 |
| De Giorgi, F | 1 |
| Ichas, F | 1 |
| Pometan, JP | 1 |
| Cambar, J | 1 |
| Vinjamuri, M | 1 |
| Adumala, RR | 1 |
| Altaha, R | 2 |
| Hobbs, GR | 1 |
| Crowell, EB | 1 |
| Kartashev, AV | 1 |
| Vinogradov, VM | 1 |
| Than, KD | 1 |
| Laterra, J | 1 |
| Kleinberg, LR | 1 |
| Grossman, SA | 5 |
| Quetin, P | 1 |
| Heymann, S | 1 |
| Karamanoukian, D | 1 |
| Schott, R | 2 |
| Bajolet, O | 1 |
| Theret, E | 1 |
| Eap, C | 1 |
| Peruzzi, P | 1 |
| Rousseaux, P | 1 |
| Gonzalez, LF | 1 |
| Gonzalez, F | 1 |
| Brachman, DG | 1 |
| Thomas, T | 1 |
| Coons, SW | 1 |
| Battaglia, M | 1 |
| Scheck, A | 1 |
| Quinn, JA | 5 |
| Jiang, SX | 1 |
| Carter, J | 1 |
| Desjardins, A | 2 |
| Vredenburgh, JJ | 2 |
| Rich, JN | 6 |
| Gururangan, S | 4 |
| Friedman, AH | 6 |
| Bigner, DD | 9 |
| Sampson, JH | 4 |
| McLendon, RE | 4 |
| Herndon, JE | 6 |
| Threatt, S | 1 |
| Friedman, HS | 10 |
| van den Bent, MJ | 2 |
| Brandes, AA | 8 |
| Rampling, R | 2 |
| Kouwenhoven, MC | 1 |
| Kros, JM | 1 |
| Carpentier, AF | 1 |
| Clement, PM | 1 |
| Frenay, M | 1 |
| Campone, M | 1 |
| Baurain, JF | 1 |
| Armand, JP | 1 |
| Taphoorn, MJ | 1 |
| Tosoni, A | 5 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Lacombe, D | 1 |
| Gorlia, T | 1 |
| Gaviani, P | 3 |
| Lamperti, EA | 1 |
| Eoli, M | 3 |
| Falcone, C | 1 |
| Dimeco, F | 2 |
| Milanesi, IM | 1 |
| Erbetta, A | 2 |
| Boiardi, A | 6 |
| Fariselli, L | 4 |
| Salmaggi, A | 7 |
| Affronti, ML | 4 |
| Heery, CR | 1 |
| Corn, BW | 1 |
| Wang, M | 2 |
| Fox, S | 1 |
| Michalski, J | 1 |
| Kresl, J | 1 |
| Mehta, M | 2 |
| Movsas, B | 2 |
| Coulibaly, B | 1 |
| Nanni, I | 1 |
| Fina, F | 1 |
| Eudes, N | 1 |
| Giorgi, R | 1 |
| Barrie, M | 2 |
| Chinot, O | 2 |
| Fuentes, S | 1 |
| Dufour, H | 2 |
| Ouafik, L | 1 |
| Figarella-Branger, D | 2 |
| Zheng, LT | 1 |
| Lee, S | 1 |
| Yin, GN | 1 |
| Mori, K | 1 |
| Suk, K | 1 |
| Jaeckle, KA | 4 |
| Ballman, KV | 3 |
| Giannini, C | 1 |
| Schomberg, PJ | 3 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| McGovern, RM | 1 |
| Safgren, SL | 1 |
| Galanis, E | 1 |
| Uhm, JH | 1 |
| Brown, PD | 1 |
| Hammack, JE | 1 |
| Arusell, R | 1 |
| Nikcevich, DA | 1 |
| Morton, RF | 2 |
| Wender, DB | 1 |
| Buckner, JC | 3 |
| Reithmeier, T | 1 |
| Graf, E | 1 |
| Piroth, T | 1 |
| Trippel, M | 1 |
| Pinsker, MO | 1 |
| Nikkhah, G | 1 |
| Morandi, L | 1 |
| Franceschi, E | 2 |
| de Biase, D | 1 |
| Marucci, G | 1 |
| Ermani, M | 5 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Brandes, A | 1 |
| Feng, X | 1 |
| Zhang, B | 1 |
| Wang, J | 2 |
| Xu, X | 1 |
| Lin, N | 1 |
| Liu, H | 1 |
| Liu, HL | 2 |
| Hua, MY | 1 |
| Chen, PY | 1 |
| Chu, PC | 1 |
| Pan, CH | 1 |
| Yang, HW | 1 |
| Huang, CY | 2 |
| Wang, JJ | 1 |
| Yen, TC | 2 |
| Wei, KC | 3 |
| Mihaliak, AM | 1 |
| Gilbert, CA | 1 |
| Li, L | 1 |
| Daou, MC | 1 |
| Moser, RP | 1 |
| Reeves, A | 1 |
| Cochran, BH | 1 |
| Ross, AH | 1 |
| Jin, G | 1 |
| Cook, S | 1 |
| Cui, B | 1 |
| Chen, WC | 1 |
| Keir, ST | 1 |
| Killela, P | 1 |
| Di, C | 1 |
| Payne, CA | 2 |
| Gregory, SG | 1 |
| McLendon, R | 1 |
| Yan, H | 1 |
| Kunwar, S | 1 |
| Chang, S | 1 |
| Vogelbaum, M | 1 |
| Sampson, J | 2 |
| Barnett, G | 1 |
| Shaffrey, M | 1 |
| Piepmeier, J | 2 |
| Prados, M | 3 |
| Croteau, D | 1 |
| Pedain, C | 1 |
| Leland, P | 1 |
| Husain, SR | 1 |
| Joshi, BH | 1 |
| Puri, RK | 1 |
| Márquez-Rivas, J | 3 |
| Ramirez, G | 2 |
| Ollero-Ortiz, A | 1 |
| Giménez-Pando, J | 1 |
| Emmerich, J | 1 |
| Quiroga-Cantero, E | 1 |
| Rivas, E | 1 |
| Gómez-González, E | 1 |
| Puchner, MJ | 1 |
| Lohmann, F | 1 |
| Schütze, M | 1 |
| Koll, S | 1 |
| Buchalla, R | 1 |
| Rainov, N | 1 |
| Kantelhardt, SR | 2 |
| Rohde, V | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 2 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 3 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, MY | 1 |
| Clark, AJ | 1 |
| Chan, DC | 1 |
| Ware, JL | 1 |
| Holt, SE | 1 |
| Chidambaram, A | 1 |
| Fillmore, HL | 1 |
| Broaddus, WC | 1 |
| Nagaiah, G | 1 |
| Almubarak, M | 1 |
| Khan, M | 1 |
| Chaichana, KK | 1 |
| Bennett, R | 1 |
| Li, J | 1 |
| Won, M | 1 |
| Shaw, EG | 1 |
| Coughlin, C | 2 |
| Figueiredo, EG | 1 |
| Faria, JW | 1 |
| Teixeira, MJ | 1 |
| O'Brien, D | 1 |
| Cotter, M | 1 |
| Lim, CH | 1 |
| Sattar, MT | 1 |
| Smyth, E | 1 |
| Fitzpatrick, F | 1 |
| Yao, D | 1 |
| Zhao, H | 1 |
| Zhang, F | 1 |
| Chen, J | 1 |
| Jiang, X | 1 |
| Zhu, X | 1 |
| Cohnen, J | 1 |
| Keric, N | 1 |
| Liang, CT | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Holdhoff, M | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Achawal, S | 1 |
| Scott, I | 1 |
| Stummer, W | 1 |
| Zaidi, H | 1 |
| Pendleton, C | 1 |
| Muntasser, H | 1 |
| Liaquat, I | 1 |
| Barlow, A | 1 |
| Whittle, I | 1 |
| Duri, S | 1 |
| Milanesi, I | 3 |
| Casali, C | 2 |
| Di Meco, F | 1 |
| Ting, CY | 1 |
| Fan, CH | 1 |
| Hsieh, HY | 1 |
| Yeh, CK | 1 |
| Rivero-Garvía, M | 2 |
| Mayorga-Buiza, MJ | 1 |
| Rueda-Torres, AB | 1 |
| Pascual-Argente, D | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Ulmer, S | 1 |
| Spalek, K | 1 |
| Nabavi, A | 1 |
| Schultka, S | 1 |
| Dörner, L | 1 |
| Levallet, G | 1 |
| Dugué, AE | 1 |
| Vital, A | 1 |
| Diebold, MD | 1 |
| Colin, P | 2 |
| Peruzzy, P | 1 |
| Bernaudin, M | 1 |
| Chapon, F | 1 |
| Guillamo, JS | 1 |
| Miglierini, P | 1 |
| Bouchekoua, M | 1 |
| Rousseau, B | 1 |
| Malhaire, JP | 1 |
| Pradier, O | 1 |
| McPherson, CM | 1 |
| Gerena-Lewis, M | 1 |
| Breneman, JC | 2 |
| Warnick, RE | 3 |
| Ironside, C | 1 |
| Karponi, G | 1 |
| d'Avella, D | 1 |
| DellaPuppa, A | 1 |
| De Bonis, P | 1 |
| Anile, C | 1 |
| Pompucci, A | 1 |
| Fiorentino, A | 1 |
| Balducci, M | 1 |
| Chiesa, S | 1 |
| Maira, G | 1 |
| Mangiola, A | 1 |
| Kuhnhenn, J | 1 |
| Kowalski, T | 1 |
| Steenken, S | 1 |
| Ostermann, K | 1 |
| Schlegel, U | 1 |
| Preukschas, M | 1 |
| Hagel, C | 1 |
| Schulte, A | 1 |
| Weber, K | 1 |
| Lamszus, K | 2 |
| Sievert, H | 1 |
| Pällmann, N | 1 |
| Bokemeyer, C | 1 |
| Hauber, J | 1 |
| Braig, M | 1 |
| Balabanov, S | 1 |
| He, P | 1 |
| Fang, L | 1 |
| Su, Z | 1 |
| Dunn, L | 1 |
| Ashkan, K | 1 |
| Jenkinson, M | 1 |
| Smith, P | 1 |
| Safdar, S | 1 |
| Tu, NH | 1 |
| Taite, LJ | 1 |
| Yuan, S | 1 |
| Wang, F | 1 |
| Chen, G | 1 |
| Feng, L | 1 |
| Colman, H | 1 |
| Keating, MJ | 1 |
| Li, X | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Marchetti, M | 1 |
| Solero, CL | 4 |
| Maccagnano, C | 1 |
| Guzzetti, S | 1 |
| Pollo, B | 1 |
| Ciusani, E | 2 |
| Afra, D | 2 |
| Sipos, L | 2 |
| Vitanovics, D | 2 |
| Khoshyomn, S | 1 |
| Nathan, D | 1 |
| Manske, GC | 1 |
| Osler, TM | 1 |
| Penar, PL | 1 |
| Chakravarti, A | 1 |
| Chakladar, A | 1 |
| Delaney, MA | 1 |
| Latham, DE | 1 |
| Loeffler, JS | 1 |
| Silber, JR | 1 |
| Bobola, MS | 1 |
| Blank, A | 1 |
| Schoeler, KD | 1 |
| Haroldson, PD | 1 |
| Huynh, MB | 1 |
| Kolstoe, DD | 1 |
| Beech, DJ | 1 |
| Madan, AK | 1 |
| Aliabadi-Wahle, S | 1 |
| Hays, AN | 1 |
| Long, WP | 1 |
| Ramirez, JL | 1 |
| Taron, M | 1 |
| Roussos, Y | 1 |
| Ariza, A | 1 |
| Ballester, R | 1 |
| Sarries, C | 1 |
| Mendez, P | 1 |
| Sanchez, JJ | 1 |
| Durando, X | 2 |
| Lemaire, JJ | 1 |
| Tortochaux, J | 1 |
| Van-Praagh, I | 1 |
| Kwiatkowski, F | 2 |
| Vincent, C | 1 |
| Bailly, C | 1 |
| Verrelle, P | 2 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Bay, JO | 2 |
| O'Neill, A | 1 |
| Grunnet, M | 1 |
| Pearlman, JL | 1 |
| Wagner, H | 1 |
| Gilbert, M | 1 |
| Newton, HB | 1 |
| Hellman, R | 1 |
| Hilt, D | 3 |
| Prados, MD | 3 |
| Yung, WK | 2 |
| Fine, HA | 1 |
| Greenberg, HS | 3 |
| Junck, L | 1 |
| Chang, SM | 2 |
| Nicholas, MK | 1 |
| Robins, HI | 1 |
| Kuhn, J | 1 |
| Hess, KR | 1 |
| Schold, SC | 6 |
| Yang, DI | 2 |
| Chen, SD | 1 |
| Yang, YT | 1 |
| Ju, TC | 1 |
| Xu, JM | 1 |
| Hsu, CY | 2 |
| Kucinski, T | 1 |
| Knopp, U | 1 |
| Goldbrunner, R | 1 |
| Hamel, W | 1 |
| Tonn, JC | 1 |
| Vredenburgh, J | 2 |
| Provenzale, JM | 4 |
| Walker, A | 2 |
| Badruddoja, M | 1 |
| Tourt-Uhlig, S | 4 |
| Dowell, JM | 1 |
| Jackson, S | 2 |
| Allen, D | 2 |
| Ziegler, K | 2 |
| Silverman, S | 1 |
| Bohlin, C | 2 |
| Schweitzer, H | 1 |
| Lentz, C | 1 |
| Leuraud, P | 1 |
| Taillandier, L | 1 |
| Medioni, J | 1 |
| Aguirre-Cruz, L | 1 |
| Crinière, E | 1 |
| Marie, Y | 1 |
| Kujas, M | 1 |
| Golmard, JL | 1 |
| Duprez, A | 1 |
| Delattre, JY | 2 |
| Sanson, M | 1 |
| Poupon, MF | 1 |
| Raizer, JJ | 1 |
| Malkin, MG | 2 |
| Kleber, M | 1 |
| Abrey, LE | 1 |
| Souhami, L | 1 |
| Seiferheld, W | 2 |
| Brachman, D | 1 |
| Podgorsak, EB | 1 |
| Werner-Wasik, M | 1 |
| Lustig, R | 1 |
| Schultz, CJ | 1 |
| Sause, W | 1 |
| Okunieff, P | 1 |
| Buckner, J | 1 |
| Zamorano, L | 2 |
| Amistà, P | 5 |
| Nicolardi, L | 3 |
| Grosso, D | 1 |
| Basso, U | 2 |
| Reni, M | 1 |
| Valduga, F | 1 |
| Monfardini, S | 3 |
| Sotti, G | 1 |
| Horvath, Z | 1 |
| Bauer, W | 1 |
| Hoechtl, T | 1 |
| Saiko, P | 1 |
| Fritzer-Szekeres, M | 1 |
| Tihan, T | 1 |
| Szekeres, T | 1 |
| Lustig, RA | 2 |
| Scott, CB | 3 |
| Gu, B | 1 |
| DeAngelis, LM | 2 |
| Liau, CT | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Vordermark, D | 1 |
| Kölbl, O | 1 |
| Choi, K | 3 |
| Siegel, M | 2 |
| Piper, JL | 1 |
| Yuan, L | 3 |
| Cho, E | 1 |
| Strnad, P | 1 |
| Omary, B | 1 |
| Rich, KM | 4 |
| Khosla, C | 3 |
| Couprie, C | 1 |
| Muracciole, X | 1 |
| Hoang-Xuan, K | 1 |
| Braguer, D | 1 |
| Martin, PM | 1 |
| Peragut, JC | 2 |
| Grisoli, F | 1 |
| Kondziolka, D | 2 |
| Lunsford, LD | 2 |
| Flickinger, JC | 1 |
| Limentani, SA | 1 |
| Asher, A | 1 |
| Heafner, M | 1 |
| Kim, JW | 1 |
| Fraser, R | 1 |
| Ashby, L | 1 |
| LaRocca, R | 1 |
| Ryken, T | 1 |
| Fadeev, BP | 1 |
| Zhabina, RM | 1 |
| Webster, M | 1 |
| Cairncross, G | 1 |
| Gertler, S | 1 |
| Perry, J | 1 |
| Wainman, N | 1 |
| Eisenhauer, E | 1 |
| Zheng, X | 2 |
| Higashikubo, R | 2 |
| Chicoine, MR | 1 |
| Lytle, RA | 1 |
| Jiang, Z | 1 |
| Marshall, NE | 1 |
| Michalak, JC | 2 |
| Burton, GV | 2 |
| Sandler, HM | 2 |
| Cascino, TL | 2 |
| Bredel, M | 1 |
| Bredel, C | 1 |
| Juric, D | 1 |
| Duran, GE | 1 |
| Yu, RX | 1 |
| Harsh, GR | 1 |
| Vogel, H | 1 |
| Recht, LD | 1 |
| Scheck, AC | 2 |
| Sikic, BI | 1 |
| Riddle, V | 1 |
| Bortey, E | 1 |
| Sotelo, J | 3 |
| Briceño, E | 1 |
| López-González, MA | 1 |
| Ducray, F | 2 |
| Cartalat-Carel, S | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Trouillas, P | 1 |
| Diedrich, A | 1 |
| König, F | 1 |
| Schulz, TG | 1 |
| Ludwig, HC | 1 |
| Herken, R | 1 |
| Quondamatteo, F | 1 |
| Hawkins, RB | 1 |
| Scheithauer, BW | 2 |
| Marks, RS | 1 |
| O'Fallon, JR | 2 |
| Bodell, WJ | 2 |
| Bodell, AP | 1 |
| Giannini, DD | 2 |
| Dyke, JP | 1 |
| Sanelli, PC | 1 |
| Voss, HU | 1 |
| Serventi, JV | 1 |
| Stieg, PE | 1 |
| Schwartz, TH | 1 |
| Ballon, D | 1 |
| Shungu, DC | 1 |
| Pannullo, SC | 1 |
| Miller, CR | 1 |
| Jackson, EN | 1 |
| Piwnica-Worms, D | 1 |
| Redjal, N | 1 |
| Chan, JA | 1 |
| Segal, RA | 1 |
| Kung, AL | 1 |
| Jacques-Olivier, B | 1 |
| Linassier, C | 2 |
| Claude, L | 1 |
| Biron, P | 2 |
| Pierre, B | 1 |
| Xavier, D | 1 |
| Pierre, V | 1 |
| Fabrice, K | 1 |
| Rosti, G | 1 |
| Giovanni, R | 1 |
| Demirer, T | 1 |
| Taner, D | 1 |
| Ng, WH | 1 |
| Wan, GQ | 1 |
| Too, HP | 1 |
| Berkey, B | 1 |
| Yung, AW | 1 |
| Scarantino, C | 1 |
| Jones, CU | 1 |
| Simpson, JR | 1 |
| Fishbach, J | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Aoki, T | 1 |
| Hashimoto, N | 1 |
| Matsutani, M | 1 |
| Balzarotti, M | 1 |
| Calatozzolo, C | 1 |
| de Grazia, U | 1 |
| Croci, D | 1 |
| Darakchiev, BJ | 1 |
| Albright, RE | 2 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Pan, E | 1 |
| Mitchell, SB | 1 |
| Tsai, JS | 1 |
| Kobiakov, GL | 1 |
| Smith, BH | 2 |
| Vaughan, M | 1 |
| Greenwood, MA | 1 |
| Kornblith, PL | 3 |
| Robinson, A | 1 |
| Shitara, N | 1 |
| McKeever, PE | 1 |
| Mortimer, JE | 1 |
| Hewlett, JS | 1 |
| Bay, J | 1 |
| Livingston, RB | 2 |
| Kobayashi, S | 1 |
| Hoshino, T | 2 |
| Dougherty, DV | 2 |
| Rosenblum, ML | 5 |
| Stewart, DJ | 1 |
| Benoit, B | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Dennery, J | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Grahovac, Z | 1 |
| Belanger, G | 1 |
| Maroun, JA | 1 |
| Kessinger, A | 2 |
| Gerosa, M | 1 |
| Reese, C | 1 |
| Barger, GR | 1 |
| Davis, RL | 5 |
| Levin, VA | 10 |
| Wilson, CB | 10 |
| Dietz, R | 1 |
| Burger, L | 1 |
| Schimrigk, K | 1 |
| Merkel, KH | 1 |
| Kelly, KA | 1 |
| Kirkwood, JM | 1 |
| Kapp, DS | 1 |
| Dara, P | 1 |
| Slater, LM | 1 |
| Talreja, D | 1 |
| Armentrout, SA | 1 |
| Dougherty, DA | 1 |
| Deen, DF | 1 |
| Hochberg, FH | 3 |
| Parker, LM | 1 |
| Takvorian, T | 1 |
| Canellos, GP | 1 |
| Zervas, NT | 1 |
| Carella, AM | 1 |
| Giordano, D | 1 |
| Santini, G | 1 |
| Frassoni, F | 1 |
| Podestà, M | 1 |
| Van Lint, MT | 1 |
| Bacigalupo, A | 1 |
| Nati, S | 1 |
| Vimercati, R | 1 |
| Occhini, D | 1 |
| Bistolfi, F | 1 |
| Lucarelli, G | 1 |
| Lercari, G | 1 |
| Marmont, AM | 1 |
| Lieberman, AN | 1 |
| Foo, SH | 1 |
| Ransohoff, J | 2 |
| Wise, A | 1 |
| George, A | 1 |
| Gordon, W | 1 |
| Walker, R | 1 |
| Salcman, M | 3 |
| Kaplan, RS | 2 |
| Ducker, TB | 2 |
| Abdo, H | 1 |
| Montgomery, E | 1 |
| Samaras, GM | 1 |
| Broadwell, RD | 1 |
| Salazar, OM | 1 |
| VanHoutte, PJ | 1 |
| Bennett, JM | 1 |
| Rubin, P | 2 |
| Wheeler, KT | 1 |
| Gamel-Bentzel, C | 1 |
| Phillips, TW | 1 |
| Chandler, WF | 1 |
| Kindt, GW | 1 |
| Ensminger, WD | 2 |
| Seeger, JF | 1 |
| Doan, KM | 1 |
| Gyves, JW | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 2 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Vincent, FM | 1 |
| West, CR | 1 |
| Avellanosa, AM | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Kapp, JP | 2 |
| Vance, R | 1 |
| Rana, SR | 1 |
| Haddy, TB | 1 |
| Ashayeri, E | 1 |
| Goldson, AL | 1 |
| Mehta, BM | 1 |
| Beikman, MK | 1 |
| Shapiro, JR | 4 |
| Jeremic, B | 4 |
| Antunovic, V | 3 |
| Djuric, L | 4 |
| Shibamoto, Y | 3 |
| Shi, X | 1 |
| Zhang, J | 1 |
| Schem, BC | 1 |
| Roszinski, S | 1 |
| Krossnes, BK | 1 |
| Mella, O | 1 |
| Marathi, UK | 1 |
| Dolan, ME | 6 |
| Erickson, LC | 2 |
| Stojanovic, M | 2 |
| Aas, AT | 1 |
| Brun, A | 1 |
| Pero, RW | 1 |
| Salford, LG | 1 |
| De Witte, O | 2 |
| Hildebrand, J | 2 |
| Luxen, A | 1 |
| Goldman, S | 1 |
| Pegg, AE | 4 |
| Moschel, RC | 4 |
| Vishnuvajjala, BR | 1 |
| Flora, KP | 1 |
| Grever, MR | 1 |
| Fleig, MJ | 1 |
| Feuerstein, BG | 1 |
| Basu, HS | 1 |
| Luk, GD | 1 |
| Casero, RA | 1 |
| Marton, LJ | 1 |
| Steward, W | 1 |
| Paul, J | 1 |
| Macham, MA | 1 |
| Harvey, E | 1 |
| Eckley, D | 1 |
| Ali-Osman, F | 5 |
| Berger, MS | 1 |
| Rajagopal, S | 1 |
| Spence, A | 1 |
| Nelson, DF | 3 |
| Scott, C | 2 |
| Nelson, JS | 3 |
| Weinstein, AS | 1 |
| Ahmad, K | 1 |
| Constine, LS | 1 |
| Murray, K | 1 |
| Powlis, WD | 1 |
| Mohiuddin, M | 1 |
| Rozental, JM | 1 |
| Cohen, JD | 1 |
| Levine, RL | 1 |
| Hanson, JM | 1 |
| Nickles, RJ | 1 |
| Pu, PY | 2 |
| Mohamed, AN | 2 |
| Galicich, JH | 1 |
| Ebrahim, SA | 2 |
| Shapiro, WR | 6 |
| Halperin, EC | 2 |
| Gaspar, L | 2 |
| Imperato, J | 2 |
| Salter, M | 2 |
| Herndon, J | 2 |
| Dowling, S | 1 |
| Brown, M | 1 |
| Vick, N | 1 |
| Cairncross, JG | 2 |
| Macdonald, DR | 1 |
| Fischer, B | 1 |
| Dropcho, E | 1 |
| Rosenfeld, S | 1 |
| Morowitz, R | 1 |
| Hait, W | 1 |
| Byrne, T | 1 |
| Khandekar, J | 1 |
| Paleologos, N | 1 |
| Bentel, GC | 1 |
| Friedman, A | 1 |
| Wedge, SR | 1 |
| Newlands, ES | 1 |
| Farnan, NC | 1 |
| Murray, KJ | 2 |
| Fischbach, AJ | 1 |
| Lee, SM | 1 |
| Reid, H | 1 |
| Elder, RH | 1 |
| Thatcher, N | 1 |
| Margison, GP | 1 |
| Lunardi, P | 1 |
| Osman Farah, J | 1 |
| Mastronardi, L | 1 |
| Puzzilli, F | 1 |
| Lo Bianco, FM | 1 |
| Del Bufalo, D | 1 |
| Biroccio, A | 2 |
| Soddu, S | 2 |
| Laudonio, N | 1 |
| D'Angelo, C | 2 |
| Sacchi, A | 2 |
| Zupi, G | 2 |
| Fernández-Hidalgo, OA | 1 |
| Vanaclocha, V | 1 |
| Vieitez, JM | 1 |
| Aristu, JJ | 1 |
| Rebollo, J | 1 |
| Gúrpide, A | 1 |
| Aramendía, JM | 1 |
| Moreno-Palanques, R | 1 |
| Martín-Algarra, S | 1 |
| Subirá, ML | 1 |
| Brugarolas, A | 1 |
| Liang, BC | 2 |
| Benboubker, L | 1 |
| Velut, S | 1 |
| Calais, G | 1 |
| Saudeau, D | 1 |
| Jan, M | 1 |
| Autret, A | 1 |
| Berger, C | 1 |
| Colombat, P | 1 |
| Rigon, A | 3 |
| Zampieri, P | 3 |
| Scelzi, E | 2 |
| Rotilio, A | 2 |
| Gardiman, M | 1 |
| Fiorentino, MV | 2 |
| Kurpad, SN | 1 |
| Archer, GE | 1 |
| Hochberg, F | 1 |
| Russell, C | 1 |
| Weissman, D | 1 |
| Evans, R | 1 |
| Cook, P | 1 |
| Burton, G | 1 |
| Eisenberg, PD | 1 |
| Valenzuela, R | 1 |
| Verkh, L | 1 |
| Elliott, TE | 1 |
| Dinapoli, RP | 1 |
| Krook, JE | 1 |
| Earle, JD | 2 |
| Levitt, R | 1 |
| Tschetter, LK | 1 |
| Pfeifle, DM | 1 |
| Twito, DI | 1 |
| Nelimark, RA | 1 |
| Wharam, M | 2 |
| Sheidler, V | 1 |
| Kleinberg, L | 2 |
| Zeltzman, M | 2 |
| Yue, N | 1 |
| Piantadosi, S | 2 |
| Chintala, SK | 2 |
| Mohanam, S | 1 |
| Rayford, A | 2 |
| Go, Y | 2 |
| Gokaslan, ZL | 1 |
| Gagercas, E | 2 |
| Venkaiah, B | 2 |
| Sawaya, R | 2 |
| Nicolson, GL | 2 |
| Rao, JS | 2 |
| Gokaslan, Z | 1 |
| Donahue, B | 1 |
| Rotman, M | 1 |
| Banker, FL | 1 |
| Fischbach, JA | 1 |
| Asbell, SO | 1 |
| Markoe, AM | 1 |
| Curran, W | 2 |
| Larson, DA | 1 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 1 |
| Wara, WM | 4 |
| Mack, EE | 1 |
| Krouwer, HG | 1 |
| Chandler, KL | 1 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Gutin, PH | 3 |
| Phillips, TL | 1 |
| Carollo, C | 1 |
| Altavilla, G | 1 |
| Turazzi, S | 2 |
| Chierichetti, F | 1 |
| Florentino, MV | 1 |
| Sahmoud, T | 1 |
| Ullyatt, E | 1 |
| Ruan, S | 2 |
| Okcu, MF | 2 |
| Ren, JP | 1 |
| Chiao, P | 1 |
| Andreeff, M | 2 |
| Levin, V | 3 |
| Zhang, W | 2 |
| Leweke, F | 1 |
| Damian, MS | 1 |
| Schindler, C | 1 |
| Schachenmayr, W | 1 |
| Eyre, HJ | 2 |
| Townsend, JJ | 1 |
| Schulman, S | 1 |
| Knudson, HM | 1 |
| Belanich, M | 1 |
| Yarosh, DB | 1 |
| Bearman, SI | 1 |
| Giroux, DJ | 1 |
| Gundersen, S | 1 |
| Lote, K | 1 |
| Watne, K | 4 |
| Pong, RC | 1 |
| Hsieh, JT | 1 |
| Guevara, P | 2 |
| Reyes, S | 1 |
| Ortiz, A | 1 |
| Rembao, D | 2 |
| Chan, JY | 1 |
| Pozzi, A | 2 |
| Broggi, G | 2 |
| Grovas, AC | 1 |
| Boyett, JM | 1 |
| Lindsley, K | 1 |
| Rosenblum, M | 1 |
| Yates, AJ | 1 |
| Finlay, JL | 2 |
| Quan, D | 1 |
| Hackney, DB | 1 |
| Pruitt, AA | 2 |
| Lenkinski, RE | 1 |
| Cecil, KM | 1 |
| Subach, BR | 1 |
| Witham, TF | 1 |
| Bozik, M | 1 |
| Schiff, D | 1 |
| Bufalo, DD | 1 |
| Ricca, A | 1 |
| D'Orazi, G | 1 |
| da Rocha, AB | 1 |
| Mans, DR | 1 |
| Bernard, EA | 1 |
| Ruschel, C | 1 |
| Logullo, AF | 1 |
| Wetmore, LA | 1 |
| Leyva, A | 1 |
| Schwartsmann, G | 1 |
| Lassen, U | 1 |
| Kristjansen, PE | 1 |
| Wagner, A | 1 |
| Kosteljanetz, M | 1 |
| Poulsen, HS | 1 |
| Durmaz, R | 1 |
| Deliorman, S | 1 |
| Uyar, R | 1 |
| Işiksoy, S | 1 |
| Erol, K | 1 |
| Tel, E | 1 |
| Bauman, GS | 1 |
| MacDonald, W | 1 |
| Moore, E | 1 |
| Ramsey, DA | 1 |
| Fisher, BJ | 1 |
| Amberger, VR | 1 |
| Del Maestro, RM | 1 |
| Rieger, L | 1 |
| Rieger, J | 1 |
| Winter, S | 1 |
| Streffer, J | 1 |
| Esser, P | 1 |
| Dichgans, J | 1 |
| Meyermann, R | 1 |
| Weller, M | 1 |
| Napolitano, M | 1 |
| Keime-Guibert, F | 1 |
| Monjour, A | 1 |
| Lafitte, C | 1 |
| Ameri, A | 1 |
| Cornu, P | 1 |
| Broët, P | 1 |
| Vlassenko, AG | 1 |
| Thiessen, B | 1 |
| Beattie, BJ | 1 |
| Blasberg, RG | 1 |
| Strawn, LM | 1 |
| Kabbinavar, F | 1 |
| Schwartz, DP | 1 |
| Mann, E | 1 |
| Shawver, LK | 1 |
| Slamon, DJ | 1 |
| Cherrington, JM | 1 |
| Pluda, J | 1 |
| Ewesuedo, RB | 1 |
| Long, L | 1 |
| Cokgor, I | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Ashley, DM | 1 |
| Stewart, ES | 1 |
| Garcia-Turner, AM | 1 |
| Langer, C | 1 |
| Coia, L | 1 |
| Teicher, BA | 1 |
| Menon, K | 1 |
| Alvarez, E | 1 |
| Galbreath, E | 1 |
| Shih, C | 1 |
| Faul, M | 1 |
| Kokkinakis, DM | 1 |
| Hoffman, RM | 1 |
| Frenkel, EP | 1 |
| Wick, JB | 1 |
| Han, Q | 1 |
| Xu, M | 1 |
| Tan, Y | 1 |
| Schäfer, C | 1 |
| Fels, C | 1 |
| Brucke, M | 1 |
| Holzhausen, HJ | 1 |
| Bahn, H | 1 |
| Wellman, M | 1 |
| Visvikis, A | 1 |
| Fischer, P | 1 |
| Rainov, NG | 1 |
| Hassenbusch, S | 1 |
| Cokgor, L | 1 |
| Edwards, S | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Qin, D | 1 |
| Mo, H | 1 |
| Ou, G | 1 |
| Lesniak, MS | 1 |
| Vogelhuber, W | 1 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Buschauer, A | 1 |
| Göpferich, A | 1 |
| Yin, JH | 1 |
| Mishra, S | 1 |
| Mishra, R | 1 |
| Tamariz, J | 1 |
| Rivera, E | 1 |
| Pasetto, LM | 1 |
| Guglielmi, B | 1 |
| Volpin, L | 1 |
| Iuzzolino, P | 1 |
| Pinna, G | 1 |
| Bloom, HJ | 2 |
| Crafts, DC | 1 |
| Schultz, MJ | 1 |
| Boldrey, EB | 3 |
| Enot, KJ | 2 |
| Pischer, TL | 4 |
| Seager, M | 2 |
| Elashoff, RM | 1 |
| Young, DF | 1 |
| Weiss, HD | 1 |
| Walker, MD | 1 |
| Schmidt, CG | 1 |
| Vogl, SE | 1 |
| Lemon, HM | 1 |
| Foley, JF | 1 |
| Bellot, PA | 1 |
| Valdiserri, RO | 1 |
| Basler, GA | 1 |
| Chernik, NL | 1 |
| Posner, JB | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Brambilla, C | 2 |
| Vaghi, A | 2 |
| Valagussa, P | 2 |
| Morello, G | 2 |
| Bonadonna, G | 2 |
| Davis, R | 2 |
| Irwin, L | 2 |
| Paillas, JE | 1 |
| Prince, MA | 1 |
| Hassoun, J | 1 |
| Pellet, W | 1 |
| Wara, W | 1 |
| Hannisdal, E | 1 |
| Nome, O | 2 |
| Hager, B | 3 |
| Hirschberg, H | 2 |
| Bradac, GB | 1 |
| Soffietti, R | 1 |
| Riva, A | 1 |
| Stura, G | 1 |
| Sales, S | 1 |
| Schiffer, D | 1 |
| Felker, GM | 1 |
| Rich, J | 1 |
| Tamada, J | 1 |
| Munari, L | 1 |
| Botturi, M | 1 |
| August, C | 1 |
| Packer, R | 1 |
| Zimmerman, R | 1 |
| Sutton, L | 1 |
| Freid, A | 1 |
| Rorke, L | 1 |
| Bayever, E | 1 |
| Kamani, N | 1 |
| Kramer, E | 1 |
| Silver, P | 2 |
| Hannigan, J | 1 |
| Recht, L | 1 |
| Fram, RJ | 1 |
| Strauss, G | 1 |
| Fitzgerald, TJ | 1 |
| Liepman, M | 1 |
| Lew, R | 1 |
| Kadish, S | 1 |
| Sherman, D | 1 |
| Wilson, J | 1 |
| Greenberger, J | 1 |
| Barjaktarević, Z | 1 |
| Mijatović, L | 1 |
| Iwata, K | 1 |
| Fields, WS | 1 |
| Geier, JM | 1 |
| Deutsch, M | 1 |
| Green, SB | 1 |
| Strike, TA | 1 |
| Burger, PC | 3 |
| Robertson, JT | 1 |
| Selker, RG | 1 |
| Mealey, J | 1 |
| Rodriguez, L | 1 |
| Chamberlain, M | 2 |
| Stuschke, M | 1 |
| Bamberg, M | 1 |
| Strehl, K | 1 |
| Budach, W | 1 |
| Sprengel, M | 1 |
| Elsås, T | 1 |
| Fostad, K | 1 |
| Katanick, D | 1 |
| Dujovny, M | 1 |
| Yakar, D | 1 |
| Malik, G | 1 |
| Ausman, JI | 1 |
| Caughlan, J | 1 |
| Gray, GS | 1 |
| Bashir, R | 1 |
| Linggood, RM | 1 |
| Hottleman, K | 1 |
| Mbidde, EK | 1 |
| Selby, PJ | 1 |
| Perren, TJ | 1 |
| Dearnaley, DP | 1 |
| Whitton, A | 1 |
| Ashley, S | 1 |
| Workman, P | 1 |
| McElwain, TJ | 1 |
| Oldfield, EH | 1 |
| Dedrick, RL | 1 |
| Chatterji, DC | 1 |
| Yeager, RL | 1 |
| Girton, ME | 1 |
| Doppman, JL | 1 |
| Miller, DF | 1 |
| Bay, JW | 1 |
| Lederman, RJ | 1 |
| Purvis, JD | 1 |
| Rogers, LR | 1 |
| Tomsak, RL | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vance, RB | 1 |
| Vestnys, P | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Beck, DO | 1 |
| DeBrun, G | 1 |
| Davis, K | 1 |
| Gerosa, MA | 2 |
| Stevanoni, G | 2 |
| Tommasi, M | 1 |
| Della Corte, V | 2 |
| Licata, C | 2 |
| Bricolo, A | 2 |
| Tridente, G | 2 |
| Marcon, C | 1 |
| Layton, PB | 1 |
| Gebarski, S | 1 |
| Meyer, M | 1 |
| Chaffee, B | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| Phillips, GL | 2 |
| Wolff, SN | 2 |
| Fay, JW | 1 |
| Herzig, RH | 1 |
| Lazarus, HM | 1 |
| Schold, C | 1 |
| Herzig, GP | 2 |
| Eltringham, JR | 1 |
| Gehan, EA | 1 |
| Vogel, FS | 1 |
| Al-Sarraf, M | 1 |
| Talley, RW | 1 |
| Costanzi, JJ | 1 |
| Athens, JW | 1 |
| Oishi, N | 1 |
| Fletcher, WS | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Berger, M | 1 |
| Mahaley, MS | 1 |
| Vick, NA | 1 |
| DeLong, ER | 1 |
| Bullard, DE | 1 |
| Khandekar, JD | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Sariban, E | 1 |
| Kohn, KW | 1 |
| Zlotogorski, C | 1 |
| Laurent, G | 1 |
| D'Incalci, M | 1 |
| Day, R | 1 |
| Strayer, DR | 1 |
| Weisband, J | 1 |
| Carter, WA | 1 |
| Black, P | 1 |
| Nidzgorski, F | 1 |
| Cook, AW | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Conley, FK | 1 |
| Jacobi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma[NCT00017147] | Phase 3 | 183 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196] | Phase 3 | 540 participants (Actual) | Interventional | 2019-03-22 | Active, not recruiting | ||
| Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-02-10 | Active, not recruiting | ||
| HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047] | Phase 1 | 6 participants (Actual) | Interventional | 2017-04-06 | Active, not recruiting | ||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590] | Phase 2 | 25 participants (Actual) | Interventional | 2019-02-15 | Active, not recruiting | ||
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959] | Phase 3 | 270 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789] | Phase 3 | 276 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576] | 28 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | |||
| Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 1998-09-30 | Completed | ||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Pilot And Phase II Trial Of Irinotecan And Radiation Followed By Irinotecan And BCNU In Glioblastoma Multiforme Patients[NCT00027612] | Phase 1/Phase 2 | 58 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00002545] | Phase 3 | 200 participants (Anticipated) | Interventional | 1994-02-28 | Completed | ||
| A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma[NCT00036660] | Phase 2 | 10 participants (Actual) | Interventional | 2002-01-10 | Completed | ||
| Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial[NCT00224978] | Phase 3 | 0 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma[NCT02432417] | Phase 2 | 0 participants (Actual) | Interventional | 2023-11-10 | Withdrawn (stopped due to The study was withdrawn due to a lack of funding. The researchers were unable to secure the necessary financial support to continue and complete the trial.) | ||
| A Phase I Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma[NCT02378532] | Phase 1 | 13 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460] | Phase 2 | 20 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas[NCT01316809] | Phase 1 | 22 participants (Actual) | Interventional | 2011-03-04 | Completed | ||
| (11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas[NCT01281982] | 2 participants (Actual) | Observational | 2011-01-13 | Terminated | |||
| Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)[NCT01468324] | Phase 1 | 14 participants (Actual) | Interventional | 2011-10-05 | Completed | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
36 reviews available for carmustine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Glioblasto | 2022 |
Biocompatible copolymer formulations to treat glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Polymers; Quality of | 2021 |
Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Drug Delivery Systems; Gli | 2019 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; D | 2014 |
Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Glioblastoma; Humans; Randomized Controlled Trials as | 2014 |
Current medical treatment of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, | 2015 |
Polymeric drug delivery for the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioblastoma; Humans; | 2015 |
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chem | 2015 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Local antitumor treatments].
Topics: Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Decanoic | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Controversies in the adjuvant therapy of high-grade gliomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
NO-mediated chemoresistance in C6 glioma cells.
Topics: Animals; Carmustine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; | 2002 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro.
Topics: Carmustine; Cell Line; Cells, Cultured; Chromosome Banding; Clone Cells; Genetic Variation; Glioblas | 1985 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
81 trials available for carmustine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Combined Mo | 2008 |
Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; DNA Modification Met | 2008 |
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Carmustine; Combined Modality Therapy; Drug A | 2009 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality T | 2009 |
[Postoperative chemoradiotherapy for cerebral glioblastoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 2008 |
Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblas
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2008 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therap | 2009 |
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2009 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Catheters, Indwelling; | 2010 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2002 |
Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 2004 |
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; | 2005 |
Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Astrocytoma; Canada; Carbon Monoxide; | 2005 |
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2006 |
Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Carriers; | 2007 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1996 |
Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Computer Simulation; Glioblastoma; | 1995 |
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Carmustine; Chemother | 1996 |
High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Brain Neoplasms; | 1996 |
High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Carmustine; Combined Mo | 1996 |
Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Mo | 1997 |
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblast | 1997 |
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1998 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1999 |
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1999 |
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Carmustine; Combine | 1999 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose Frac | 2000 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
[Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chil | 2001 |
A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2002 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Treatment of malignant glioma. A controlled study of chemotherapy and irradiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glioblasto | 1976 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Glioblastoma; Humans; Lomustine; Male | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glio | 1986 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
257 other studies available for carmustine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells.
Topics: Acridines; Animals; Carmustine; Caspase 3; Caspases; Cell Line; Cisplatin; Cross-Linking Reagents; D | 2005 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Cysts; Gliobla | 2022 |
A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma.
Topics: Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Humans; Reproducibili | 2022 |
MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioblastoma; Humans; MicroRNAs; Pro | 2022 |
2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways: In vitro and in vivo validation.
Topics: Animals; Carmustine; Deoxyglucose; Endoplasmic Reticulum Stress; Glioblastoma; Glucose; Glutathione; | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Immunom | 2022 |
Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment.
Topics: Administration, Intranasal; Animals; Brain; Carmustine; Chitosan; Drug Carriers; Drug Delivery Syste | 2022 |
CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member | 2022 |
Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture.
Topics: Carmustine; Cell Culture Techniques; Glioblastoma; Humans; Hydrogels; Lab-On-A-Chip Devices; Polyeth | 2022 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cohort Studies; C | 2023 |
3D-conformal very-high energy electron therapy as candidate modality for FLASH-RT: A treatment planning study for glioblastoma and lung cancer.
Topics: Carmustine; Electrons; Glioblastoma; Humans; Lung Neoplasms; Radiotherapy Dosage; Radiotherapy Plann | 2023 |
miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Fema | 2019 |
microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Mo | 2020 |
Reimagining external beam radiotherapy for glioblastoma: "old beam, new trick".
Topics: Carmustine; Cytarabine; Etoposide; Glioblastoma; Humans | 2021 |
Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Coho | 2021 |
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2017 |
Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Edema; Carmustine; Central Nervous System Cysts; C | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cerebral Ventric | 2017 |
Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality The | 2017 |
In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Fema | 2018 |
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliobla | 2018 |
Incomplete copolymer degradation of in situ chemotherapy.
Topics: Absorbable Implants; Adsorption; Aged; Brain Neoplasms; Carmustine; Disease Progression; Drug Delive | 2018 |
Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmu | 2018 |
How safe are carmustine wafers?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cysts; Drug Implants; Glioblastoma; | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
[Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2018 |
MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2019 |
Impact of human cytomegalovirus on glioblastoma cell viability and chemotherapy treatment.
Topics: Antineoplastic Agents; Carmustine; Cell Line, Tumor; Cell Survival; Cytomegalovirus; Gene Expression | 2018 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Topics: AC133 Antigen; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neopl | 2019 |
Letter to the Editor. How safe is Carmustine wafer implantation?
Topics: Antineoplastic Agents, Alkylating; Carmustine; Glioblastoma; Humans | 2019 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cations; | 2013 |
Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma.
Topics: Animals; Antineoplastic Agents; Arginine; Carmustine; Cell Line, Tumor; Drug Delivery Systems; Genet | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Pr | 2014 |
MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2014 |
Assessing response using 99mTc-MIBI early after interstitial chemotherapy with carmustine-loaded polymers in glioblastoma multiforme: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carmustine; Female; Glioblastoma; Humans; Mal | 2014 |
The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Carmustine; Chemoradiother | 2015 |
Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Co | 2015 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modificat | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Gliobla | 2015 |
[A Case of Symptomatic Cyst Formation after BCNU Wafer Implantation for Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cysts; Fe | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation.
Topics: Antineoplastic Agents; Astrocytes; Blood-Brain Barrier; Brain; Carmustine; Cell Line, Tumor; Delayed | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Topics: Adult; Aged; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Al | 2017 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antineoplastic Agents; Apoptosis; Brain Neoplasms; | 2008 |
Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Drug Carriers; Gliobl | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Com | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
[Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature].
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Clostridium Infection | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Brain Neoplasms; Carmustine; DNA Methylation; Drug Impl | 2009 |
Down-regulation of lipocalin 2 contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Caspase 3; Cell Cycle; Cell D | 2009 |
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free Survival; | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell | 2011 |
Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid; Con | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell C | 2010 |
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle Proteins; Child; Drug | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Carmu | 2011 |
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
Topics: Aged; Aged, 80 and over; Aging; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2011 |
Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Car | 2011 |
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; | 2010 |
Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants.
Topics: Biocompatible Materials; Brain Neoplasms; Candidiasis; Carmustine; Combined Modality Therapy; Decano | 2011 |
Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; An | 2010 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor.
Topics: Anions; Brain Neoplasms; Carmustine; Cations; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proli | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2011 |
Gliadel wafers acting as a lattice for bacterial growth: a case illustration.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Central Nervous System | 2011 |
Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Carmustine; Drug Delivery Sy | 2012 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Treatment of glioblastoma multiforme with high doses of carmustine intracavitary, in an infant.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infant | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Abscess; Brain Neoplasms; C | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemo | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic The | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle | 2012 |
A sequential testing approach to detecting multiple change points in the proportional hazards model.
Topics: Antineoplastic Agents, Alkylating; Biostatistics; Brain Neoplasms; Carmustine; Clinical Trials as To | 2013 |
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmu | 2002 |
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Combined Modality Therapy | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2003 |
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modali | 2003 |
Intracavitary chemotherapy for glioblastoma: present status and future directions.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 2003 |
Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Cobalt; Def | 2004 |
Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Topics: Absorbable Implants; Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; B | 2004 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarba | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combin | 2004 |
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
Topics: Antineoplastic Agents; Carmustine; Cell Death; Cell Line, Tumor; Cytochrome-B(5) Reductase; Dicumaro | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Huma | 2005 |
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Carmustine; Cell Line, Tumor; Dr | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
In regard to Dr. Souhami et al. (Int J Radiat Oncol Biol Phys 2004;60:853-860).
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Radi | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
Topics: Animals; Apoptosis Regulatory Proteins; Azo Compounds; Bcl-2-Like Protein 11; Brain Neoplasms; Cadav | 2005 |
Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2005 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Prote | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Mod | 2006 |
Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Female; Genotype; Glioblastoma; Glu | 2006 |
Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid | 2007 |
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Extracellular Matrix; Female; Fibron | 2007 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 2007 |
Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Communication; Cell Count; Cell | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cel | 2007 |
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines.
Topics: Adult; Brain Neoplasms; Carmustine; Cell Line; Cell Membrane; Cytoplasm; Drug Resistance; Female; Gl | 1983 |
High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Res | 1983 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Complications after combination of chemotherapy and radiation for malignant brain tumours.
Topics: Adult; Bleomycin; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Huma | 1982 |
Long-term survivors of high-grade malignant astrocytomas.
Topics: Adult; Age Factors; Astrocytoma; Brain Neoplasms; Carmustine; Evaluation Studies as Topic; Glioblast | 1980 |
Analysis of clonogenic human brain tumour cells: preliminary results of tumour sensitivity testing with BCNU.
Topics: Aged; Brain; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Female; Glioblastoma; Humans; | 1980 |
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1981 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
High dose BCNU followed by autologous bone marrow infusion in glioblastoma multiforme.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Middle Aged | 1981 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Doxorubicin; | 1982 |
Aggressive multimodality therapy based on a multicompartmental model of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Drug Therapy, Combination; Glioblastoma; Hot Temper | 1982 |
High-dose radiation therapy with low-dose (pulsed) BCNU in malignant gliomas: an Eastern Cooperative Oncology Group (ECOG) report.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cobalt Radioisotopes; Female; Glioblastoma; Humans; Male; | 1982 |
Nursing management of the patient receiving high-dose BCNU with autologous bone marrow harvest.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1982 |
New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Carotid Arteries; Chemotherapy, | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Spinal leptomeningeal invasion from intracranial glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Cauda Equina; Cerebrospinal Fluid; Child, Preschool; Cobalt Radioisotop | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Intraoperative radiotherapy in childhood malignant astrocytoma.
Topics: Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioblastoma; Humans; Intraoperative | 1984 |
BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes.
Topics: Base Sequence; Biomarkers, Tumor; Blotting, Southern; Carmustine; Chromosome Aberrations; Chromosome | 1993 |
[Analysis of three-year survivors in patients with glioblastoma].
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; China; Combined Modality Therapy; Female; Fol | 1995 |
Timing of hypertonic glucose and thermochemotherapy with 1-(4-amino-2-methylpyrimidine-5-yl) methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in the BT4An rat glioma: relation to intratumoral pH reduction and circulatory changes after glucose supply.
Topics: Animals; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Drug Administration Schedule; | 1995 |
Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Glioblastoma; Guanine; Humans; | 1994 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth.
Topics: Animals; Body Weight; Brain Neoplasms; Calmodulin; Carmustine; Cell Division; Chlorpromazine; Drug S | 1994 |
Acute effect of carmustine on glucose metabolism in brain and glioblastoma.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glucose; Humans; Male; Middle | 1994 |
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Carmustine; Child; Chromatography, High Pre | 1994 |
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Topics: Animals; Body Weight; Brain Neoplasms; Carmustine; Cell Division; Colonic Neoplasms; Drug Screening | 1994 |
Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Topics: Carmustine; Cell Survival; Cisplatin; DNA; DNA Repair; Glioblastoma; Humans; Novobiocin; Topoisomera | 1993 |
Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.
Topics: Biological Transport, Active; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality | 1993 |
Chromosome number and carmustine sensitivity in human gliomas.
Topics: Adolescent; Adult; Aged; Aneuploidy; Astrocytoma; Brain Neoplasms; Carmustine; Child; Chromosome Abe | 1993 |
BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clone Cells; Diploidy; Drug Resistance; Drug Screening Ass | 1993 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Glio | 1996 |
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carmustine; Cell Line; Doxorubicin; Drug Resista | 1996 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cisplatin; Culture Media, Seru | 1997 |
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cisplatin; Culture Media, Seru | 1997 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17.
Topics: Apoptosis; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Chromatin; Enzyme Inhibitors; | 1998 |
Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cisplatin; Cyclin- | 1998 |
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cispl | 1999 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
In vitro repair synthesis of BCNU-induced DNA damage.
Topics: Bloom Syndrome; Carmustine; DNA Damage; DNA Ligases; DNA Repair; Dose-Response Relationship, Drug; D | 1998 |
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci | 1999 |
Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combi | 1999 |
Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studi | 1999 |
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Sc | 1999 |
Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Drug Synergism; Etoposide; Gamma Rays; Glioblastom | 1999 |
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Bloc | 1999 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuva | 2000 |
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2000 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Div | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Gamma-glutamyl transferase expression in higher-grade astrocytic glioma.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain; Carmustine; | 2001 |
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Chemistry; Brain Neoplasms; Carmustine; Chromat | 2001 |
Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carm | 2002 |
Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell D | 2002 |
Glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Glioblastoma; Humans; Vincristine | 1977 |
[Polychemotherapy of glioblastoma multiforme].
Topics: Adult; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Male | 1977 |
Acute leukemia complicating treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child, Preschool; Dexamethasone; Drug Therapy, C | 1978 |
Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain.
Topics: Brain Neoplasms; Carmustine; Drug Administration Schedule; Glioblastoma; Humans; Teniposide; Vomitin | 1978 |
Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lung Diseases; Male; Middle Aged | 1979 |
Human brain tumor transplantation into nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantati | 1979 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Nitrosourea Compounds; Semustine | 1978 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Topics: Animals; Carmustine; Drug Resistance; Female; Glioblastoma; Guanine; Humans; Male; Medulloblastoma; | 1992 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Acute toxicity from BOPP (BCNU, vincristine, procarbazine, cisplatinum) chemotherapy for glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Glioblastoma; Humans; Procarb | 1990 |
In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells.
Topics: Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; Drug Screening | 1988 |
Pathology of high-dose intraarterial BCNU.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Hu | 1989 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Treatment of high grade glioma xenografts with nitrosoureas in nude mice.
Topics: Animals; Carmustine; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nimus | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Glioblastoma; Glutathione; Glutathione Transf | 1989 |
Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme.
Topics: Adult; Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Combined Modality Ther | 1988 |
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther | 1988 |
Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Glioblastoma; Hemoperfusion; | 1985 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Infusions, Intra-Arterial | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age.
Topics: Age Factors; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Chil | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Drug Resistance; Glioblastoma; Humans; Lomu | 1986 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Be | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.
Topics: Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Cross-Linking Re | 1987 |
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cell Line; Colony-Forming Units Assay; Dose-Response Relat | 1987 |
Transplantation of nervous system tumors in diffusion chambers.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Dose-Response Relationship, Drug; Dose-Response Relati | 1974 |